{"gene":"IL2RA","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1984,"finding":"Molecular cloning of the human IL-2 receptor alpha chain (IL2RA/CD25) cDNA revealed a single gene producing two mRNAs with different polyadenylation signals, and an alternatively spliced form lacking 216 bases that cannot bind IL-2; the encoded protein was expressed in COS cells and shown to bind IL-2.","method":"cDNA cloning, sequencing, expression in COS cells, IL-2 binding assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original molecular cloning with direct expression and binding validation, foundational paper >900 citations","pmids":["6090948","6090949"],"is_preprint":false},{"year":1985,"finding":"IL-2 itself upregulates cell-surface expression of its own receptor (Tac antigen/CD25) in an 8-10-fold enhancement of anti-Tac binding sites while simultaneously reducing high-affinity IL-2 binding sites; the magnitude of the proliferative response correlated with high-affinity IL-2 binding site density rather than CD25 (Tac) levels, demonstrating that IL-2–receptor interactions promote loss of IL-2 responsiveness.","method":"Radiolabeled monoclonal antibody binding assays, IL-2 binding competition, membrane proteolysis recovery assays, proliferation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal binding and functional assays, >500 citations, foundational study","pmids":["2983318"],"is_preprint":false},{"year":1987,"finding":"The IL2RA promoter contains regulatory elements between −327 and −265 that drive constitutive expression in HTLV-I-infected T cells; the HTLV-I transactivator protein (tat-I) activates IL2RA promoter constructs through a specific region (−267 to −265) in a cell-type-specific manner requiring additional cellular factors.","method":"5' deletion promoter-CAT reporter constructs, cotransfection with tat-I expression vector, cell-type specificity experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — deletion mapping with functional reporter assays, replicated across cell types, >400 citations","pmids":["3030566"],"is_preprint":false},{"year":1989,"finding":"The IL-2 receptor beta chain (IL-2Rβ, p70-75) was cloned; when co-expressed with IL-2Rα cDNA, the two chains together reconstitute a high-affinity IL-2 receptor, demonstrating that IL-2Rα and IL-2Rβ together form the high-affinity complex.","method":"cDNA cloning, co-expression of IL-2Rα and IL-2Rβ in T lymphoid cells, IL-2 binding assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — reconstitution of high-affinity receptor by co-expression, >700 citations","pmids":["2785715"],"is_preprint":false},{"year":1989,"finding":"CD25 (IL-2Rα/Tac antigen) is detectable on 15–45% of circulating human T and B lymphocytes using a highly sensitive immunofluorescence procedure, revealing constitutive low-level CD25 expression on resting lymphocytes including CD4+ T cells, CD8+ T cells, and B cells.","method":"Highly sensitive indirect immunofluorescence with three different anti-CD25 antibodies, double-marker studies for lineage identification","journal":"Immunology and cell biology","confidence":"Medium","confidence_rationale":"Tier 3 — direct localization/expression experiment, single lab but multiple antibodies and cell types","pmids":["2570038"],"is_preprint":false},{"year":1991,"finding":"A triplex-forming oligonucleotide targeting the IL2RA promoter region (−273 to −246), spanning the κB enhancer and CArG box, selectively inhibited IL2RA mRNA transcription in intact lymphocytes for up to 12 hours after PHA stimulation, as confirmed by nuclear run-on assays, demonstrating that the κB and CArG elements are required for normal IL2RA transcriptional activation.","method":"Triplex oligonucleotide designed to IL2RA promoter, EMSA for binding specificity, restriction enzyme inhibition assay, nuclear run-on transcription assays in intact lymphocytes","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (EMSA, restriction protection, nuclear run-on) confirming promoter element function","pmids":["2062658"],"is_preprint":false},{"year":1993,"finding":"CD25+ (activated) T cells are the principal producers of HIV in acutely infected PBMC cultures; elimination of the small CD25+ population (3–5%) before infection reduces p24 secretion by 99%, and killing CD25+ cells after infection virtually stops viral production and spread, while resting CD25− cells can be infected but only produce virus upon subsequent activation.","method":"Anti-CD25–ricin A chain immunotoxin (RFT5-dgA) selective depletion before/after HIV infection, p24 ELISA, coculture with H9 cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — selective depletion with immunotoxin, multiple experimental conditions, clear mechanistic readout","pmids":["8496611"],"is_preprint":false},{"year":1994,"finding":"Jak1 and Jak3 are selectively and functionally associated with distinct IL-2R subunits: Jak1 associates with the serine-rich region of IL-2Rβ and Jak3 associates with the carboxyl-terminal region of IL-2Rγ; both associations are required for IL-2 signaling, and expression of Jak3 cDNA in Jak3-negative fibroblasts bearing reconstituted IL-2R conferred IL-2 responsiveness.","method":"Co-immunoprecipitation, reconstitution in Jak3-negative fibroblasts with IL-2R subunits and Jak3 cDNA, IL-2 stimulation and tyrosine phosphorylation assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution in heterologous cells plus co-IP, >500 citations, foundational JAK-STAT signaling paper","pmids":["7973659"],"is_preprint":false},{"year":1999,"finding":"In the IL-2R signaling system, Jak3 can transphosphorylate a kinase-dead Jak1, but Jak1 cannot phosphorylate kinase-dead Jak3, suggesting Jak3 activation precedes Jak1; Jak3 phosphorylates both IL-2Rβ and IL-2Rγc, while Jak1 phosphorylates only IL-2Rβ; Jak3 activates STAT3 and STAT5 but not STAT1, whereas Jak1 activates STAT1, STAT3, and STAT5, revealing differential substrate specificity between the two kinases.","method":"Baculovirus-expressed recombinant Jak1, Jak3, and kinase-dead mutants; co-expression of IL-2R subunits; in vitro tyrosine phosphorylation assays; STAT phosphorylation analysis","journal":"Leukemia & lymphoma","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro reconstitution with recombinant proteins and kinase-dead mutants, single study","pmids":["10037026"],"is_preprint":false},{"year":2002,"finding":"CD25 (IL-2Rα) suppressive function in human thymocytes is mediated by CTLA-4 and membrane TGF-β1 acting together to inhibit IL-2Rα chain (CD25) expression on target T cells; anti-CTLA-4 or anti-TGF-β1 alone partially inhibit suppression, but the combination completely blocks it and restores CD25 expression on target cells, thereby restoring IL-2 responsiveness.","method":"Mixed lymphocyte culture suppression assays with CD4+CD25+ human thymocytes, antibody blocking experiments (anti-CTLA-4, anti-TGF-β1), flow cytometry for CD25 expression on target cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — reciprocal blocking experiments with multiple antibodies and clear mechanistic readout (CD25 re-expression on targets)","pmids":["12163566"],"is_preprint":false},{"year":2002,"finding":"CD25 (IL-2Rα) localization within membrane microdomains is proposed to switch IL-2R signaling: in the absence of CD25, IL-2R activation occurs in the soluble membrane fraction and promotes Jak3-independent, antiapoptotic signaling; when CD25 is induced by TCR signaling and localizes to microdomains with CD122, the high-affinity receptor complex activates Jak3 and shifts the balance toward proliferation versus activation-induced cell death.","method":"Review integrating published biochemical fractionation and signaling data; analysis of membrane microdomain distribution of CD25 and CD122","journal":"Immunology and cell biology","confidence":"Low","confidence_rationale":"Tier 4 — mechanistic model review without new primary experimental data","pmids":["12121224"],"is_preprint":false},{"year":2002,"finding":"SATB1 recruits the NURD histone deacetylase complex and the ACF1/ISWI nucleosome-remodeling complexes to a specific binding site in the IL-2Rα (IL2RA) locus, mediating deacetylation of histones over a large chromatin domain and regulating nucleosome positioning over 7 kilobases; in SATB1-null thymocytes, IL-2Rα is ectopically transcribed, demonstrating that SATB1 represses IL2RA through targeted chromatin remodeling.","method":"ChIP for histone acetylation, nucleosome positioning assays, SATB1 knockout mice (ectopic IL-2Rα transcription phenotype), co-recruitment of NURD/ACF1/ISWI complexes","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1-2 — multiple chromatin assays plus genetic KO with clear phenotype, >400 citations","pmids":["12374985"],"is_preprint":false},{"year":2003,"finding":"CD8+CD25+ human thymocytes suppress autologous CD25− T cell proliferation via a contact-dependent mechanism requiring CTLA-4 and membrane TGF-β1 acting together, and this suppression is mediated by inhibition of IL-2Rα (CD25) expression on target T cells—the same mechanism used by CD4+CD25+ regulatory thymocytes.","method":"Suppression assays with purified CD8+CD25+ thymocytes, antibody blocking (anti-CTLA-4 + anti-TGF-β1), flow cytometry for CD25 on target cells","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — reciprocal blocking experiments confirming mechanism, orthogonal to prior CD4+CD25+ thymocyte study","pmids":["12893750"],"is_preprint":false},{"year":2004,"finding":"IL-2R α-chain (CD25) endocytic trafficking follows a clathrin-independent pathway; after internalization, CD25/IL-2Rα recycles to the plasma membrane while IL-2Rβ and IL-2Rγ are targeted to late endosomes/lysosomes for degradation via ubiquitination as a sorting signal.","method":"Endocytosis assays, subcellular fractionation, trafficking studies distinguishing clathrin-dependent vs. independent routes, ubiquitination analysis","journal":"Current topics in microbiology and immunology","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular trafficking experiments identifying differential fates of IL-2R chains","pmids":["15645712"],"is_preprint":false},{"year":2005,"finding":"Crystal structure of the quaternary IL-2/IL-2Rα/IL-2Rβ/γc ectodomain complex at 2.3 Å resolution revealed that IL-2Rα binding to IL-2 stabilizes a secondary binding site that is presented to IL-2Rβ; γc is then recruited to the composite IL-2/IL-2Rβ surface through degenerate contacts consistent with its shared use by multiple cytokines; the structure provides a molecular rationale for X-SCID-associated loss-of-function mutations in γc.","method":"X-ray crystallography at 2.3 Å resolution of the quaternary ectodomain complex","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure of the complete quaternary complex, >400 citations","pmids":["16293754"],"is_preprint":false},{"year":2009,"finding":"CD25 (IL-2Rα) is expressed on corneal and conjunctival epithelial cells and is proteolytically cleaved to generate soluble CD25 in tears by matrix metalloproteinase 9 (MMP-9); desiccating stress increases MMP-9 activity and reduces membrane CD25 in the ocular surface epithelium; this cleavage is prevented by MMP-9 inhibition (doxycycline) and is absent in MMP-9 knockout mice, and confirmed by MMP-9 treatment of cultured corneal epithelial cells.","method":"MMP-9 knockout mice, topical MMP-9 inhibitor (doxycycline), in situ zymography, confocal immunofluorescence, Western blot of CD25 in epithelial lysates, immunobead assay for soluble CD25 in tears, MMP-9 treatment of human corneal epithelial cells","journal":"Journal of inflammation","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO, pharmacologic inhibition, and direct enzyme treatment with multiple orthogonal readouts","pmids":["19878594"],"is_preprint":false},{"year":2009,"finding":"Differences in surface IL2RA (CD25) protein expression on specific immune cell types (but not others) correlate with haplotypes in the IL2RA region associated with type 1 diabetes and multiple sclerosis; this gene-phenotype correlation was confirmed at the RNA level by allele-specific expression, demonstrating that disease-associated IL2RA variants functionally regulate CD25 protein levels in a cell-type-specific manner.","method":"Polychromatic flow cytometry for CD25 surface expression across immune cell types, genotyping of IL2RA haplotypes, allele-specific expression (ASE) analysis at RNA level","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — flow cytometry + ASE in large genotype-selectable biobank, two orthogonal methods confirming cell-type-specific regulation","pmids":["19701192"],"is_preprint":false},{"year":2012,"finding":"In vitro evolution of IL-2 generated a 'superkine' (super-2) with increased affinity for IL-2Rβ that eliminates the functional requirement for CD25; crystal structures of the superkine in free and receptor-bound forms showed evolved mutations stabilize the IL-2Rβ binding helix into a CD25-bound-like conformation; the superkine recapitulates CD25 function by eliciting STAT5 phosphorylation and T cell proliferation independent of CD25 expression.","method":"In vitro evolution (yeast display), crystal structures of IL-2 superkine free and receptor-bound, molecular dynamics simulations, STAT5 phosphorylation assays, T cell proliferation assays, in vivo antitumor models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus functional reconstitution and mutagenesis-equivalent in vitro evolution, >460 citations","pmids":["22446627"],"is_preprint":false},{"year":2013,"finding":"A patient with a novel homozygous IL2RA null mutation exhibited pronounced CD8+ T cell lymphoproliferation with activated CD8+STAT5+ T cells infiltrating tissues, impaired antigen-specific responses, and FOXP3+ Tregs that retained higher capacity to respond to IL-2 compared to other T cell subsets, demonstrating that CD25/IL-2Rα is required for normal immune homeostasis and its loss leads to disproportionate CD8+ hyperactivation despite residual Treg IL-2 responsiveness.","method":"Analysis of IL2RA null patient: flow cytometry, STAT5 phosphorylation assays, in vitro/in vivo antigen-specific response assays, skin biopsy immunohistochemistry, serum cytokine measurement","journal":"Clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — natural human loss-of-function mutation with comprehensive immunological phenotyping using multiple orthogonal methods","pmids":["23416241"],"is_preprint":false},{"year":2014,"finding":"An MS-associated IL2RA polymorphism (rs2104286) specifically increases IL-2 responsiveness of naive TH cells, measured by GM-CSF production; the variant regulates the propensity of naive TH cells to develop into GM-CSF-producing memory TH cells, mechanistically linking the IL2RA risk allele to increased neuroinflammatory TH cell function.","method":"Genotype-stratified analysis of human donor T cells; IL-2 stimulation assays; intracellular cytokine staining for GM-CSF; ex vivo differentiation assays from naive to memory TH cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — direct functional comparison of IL-2 responsiveness stratified by genotype with multiple T cell assays","pmids":["25278028"],"is_preprint":false},{"year":2016,"finding":"CD25 (IL-2Rα) expression on human peripheral blood T cells is regulated in two temporally distinct phases: an early Src kinase (TCR-associated)-dependent phase required for T cell competence and IL-2 responsiveness, and a later JAK3/STAT5-dependent phase that sustains high and prolonged CD25 expression to drive cell growth and proliferation; in competent CD25+ T cells bearing high-affinity IL-2R, IL-2 switches on a JAK3/STAT5 pathway that is constitutively JAK3-independent in quiescent cells.","method":"Selective kinase inhibitors (PP2 for Src, WHI-P131 for JAK3), flow cytometry for CD25 dynamics, STAT3/STAT5 phosphorylation assays (tyrosine phosphorylation), mitogen dose-response experiments in human peripheral blood lymphocytes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacologic dissection with selective inhibitors and multiple signaling readouts, single lab study","pmids":["27936140"],"is_preprint":false},{"year":2017,"finding":"IL-2-activated STAT5 binds to a superenhancer at the Il2ra locus and induces new chromatin looping interactions; CRISPR-Cas9 editing of three individual STAT5 binding sites within the Il2ra superenhancer in mice each decreased STAT5 binding and reduced IL-2-induced Il2ra expression, demonstrating that superenhancer elements are non-redundant and all required for normal IL2RA gene expression; STAT5-mediated chromatin looping preferentially regulates highly IL-2-inducible genes.","method":"ChIA-PET chromatin interaction sequencing, CRISPR-Cas9 deletion of superenhancer elements in mice, ChIP-seq for STAT5 binding, quantitative Il2ra mRNA expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — CRISPR-validated superenhancer elements combined with chromatin interaction mapping (ChIA-PET)","pmids":["29078395"],"is_preprint":false},{"year":2018,"finding":"In a mouse model of hemophagocytic lymphohistiocytosis (HLH), CD25 expression on hyperactivated CD8+ T cells drives the immunological (but not hematologic) features of disease through excessive IL-2 consumption; genetic elimination of CD25 substantially corrected immunologic HLH features, while hematologic features were completely dependent on IFN-γ, revealing a dichotomous pathogenic mechanism.","method":"Prf1-knockout mouse model of HLH with genetic elimination of IFN-γ production or CD25 expression; assessment of hematologic, immunologic, and physiologic disease parameters","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in mouse model with clean dissection of two pathways using separate KO conditions","pmids":["30578871"],"is_preprint":false},{"year":2019,"finding":"High-affinity TCR signaling sustains IL-2R (CD25) expression longer on naive T cells than low-affinity TCR interactions, directing them toward Th1/Th17 rather than Tfh differentiation; this TCR affinity effect on Th fate acts through direct regulation of CD25 and novel differentiation regulators (Eef1e1, Gbp2) in naive T cells, not through preferential T cell–dendritic cell interactions.","method":"Adoptive transfer of TCR transgenic T cells with defined affinity variants, flow cytometry for CD25 and Th subset markers post-infection, gene expression analysis (Eef1e1, Gbp2), DC subset interaction tracking","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo TCR affinity variants with multiple Th fate markers, single lab study","pmids":["30858199"],"is_preprint":false},{"year":2020,"finding":"IL2RA promotes proliferation, cell-cycle activity, and inhibits apoptosis in AML cells; IL2RA inhibits differentiation and promotes leukemic stem cell properties; genetic knockdown or antibody-mediated inhibition of IL2RA reduces leukemogenesis in two genetically distinct mouse AML models while sparing normal hematopoietic cells, demonstrating a cell-autonomous oncogenic role for IL2RA in AML independent of its classical immune regulatory function.","method":"Genetic manipulation (shRNA knockdown, overexpression) and antibody inhibition of IL2RA in human AML cell lines and primary patient samples; two mouse AML models (genetic knockdown); flow cytometry for differentiation and stem cell markers; proliferation, apoptosis, and cell-cycle assays; drug synergy experiments","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and pharmacologic loss-of-function approaches in human cells, primary samples, and two independent mouse models","pmids":["32873636"],"is_preprint":false},{"year":2021,"finding":"Transcription factor Bach2 directly represses CD25 (IL-2Rα) expression in regulatory T cells; Bach2 deficiency in Tregs upregulates CD25 and IL-2R signaling, which partially compensates for poor resting Treg survival; Bach2 also suppresses CD25/IL-2R signaling in T follicular regulatory (Tfr) cells, and its deficiency prevents formation of highly differentiated Tfr cells and causes aberrant germinal center responses.","method":"Bach2 conditional knockout in Tregs, ChIP for Bach2 binding at CD25/Il2ra locus, flow cytometry for CD25 and IL-2R signaling markers, Tfr cell enumeration and GC analysis, in vitro IL-2 signaling assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — direct ChIP showing Bach2 binding at Il2ra locus combined with conditional KO and multiple functional readouts","pmids":["33979619"],"is_preprint":false},{"year":2023,"finding":"Tumor-specific CD8+ T cells (TSTs) co-express elevated CD25 and PD-1 and are more susceptible to stimulation by IL-2Rα-proficient agonists than by IL-2Rβγ-biased analogs; anti-PD-1 antitumor efficacy depends on activation of PD-1+CD25+ TSTs through autocrine IL-2–CD25 signaling; IL-2Rα-biased agonists (preserving CD25 activity) restore IL-2 signaling and synergize with anti-PD-1 to eradicate large established tumors in mouse models.","method":"Comparison of IL-2 variants (wild-type, IL-2Rα-biased, IL-2Rβγ-biased, non-α) in mouse tumor models; flow cytometry for CD25/PD-1 co-expression on TSTs; autocrine IL-2 signaling blockade experiments; anti-PD-1 combination experiments; human cancer patient IL-2 signature correlations","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 — multiple IL-2 variant comparisons in vivo with mechanistic dissection of CD25 role in autocrine signaling and anti-PD-1 response","pmids":["37550516"],"is_preprint":false}],"current_model":"IL2RA (CD25) encodes the alpha chain of the high-affinity IL-2 receptor that, together with IL-2Rβ and the common γ-chain, forms a quaternary signaling complex (structurally defined at 2.3 Å) in which CD25 binding to IL-2 stabilizes a secondary surface for IL-2Rβ recruitment and γc docking, activating Jak1/Jak3 and downstream STAT5; CD25 undergoes clathrin-independent endocytic recycling (distinct from the β/γ chains which are ubiquitinated and degraded), is transcriptionally regulated by NF-κB/κB enhancers, TCR-Src kinase signals (early phase), and STAT5-bound superenhancers with chromatin looping (sustained phase), is repressed by SATB1-recruited HDAC and nucleosome-remodeling complexes and by Bach2, and is proteolytically shed as soluble CD25 by MMP-9; human IL2RA null mutation causes lymphoproliferation with hyperactivated CD8+ T cells and Treg dysfunction, and in AML cells IL2RA cell-autonomously promotes proliferation, blocks differentiation, and supports leukemic stem cell properties."},"narrative":{"teleology":[{"year":1984,"claim":"Molecular cloning of the IL2RA cDNA established that a single gene encodes the IL-2-binding α chain, resolving the molecular identity of the receptor subunit and revealing alternative splicing that abolishes ligand binding.","evidence":"cDNA cloning with expression in COS cells and IL-2 binding assay","pmids":["6090948","6090949"],"confidence":"High","gaps":["No knowledge of additional receptor subunits required for high-affinity binding","Signaling mechanism unknown","No structural information"]},{"year":1989,"claim":"Co-expression of IL-2Rα with the newly cloned IL-2Rβ reconstituted high-affinity IL-2 binding, establishing that the high-affinity receptor is a multi-subunit complex and that CD25 alone forms only the low/intermediate-affinity state.","evidence":"Co-expression of IL-2Rα and IL-2Rβ cDNAs in T lymphoid cells with IL-2 binding assays","pmids":["2785715"],"confidence":"High","gaps":["γc subunit not yet identified","No structural basis for cooperativity","Downstream signaling effectors unknown"]},{"year":1991,"claim":"Identification of κB enhancer and CArG box elements in the IL2RA promoter as essential cis-regulatory regions established the first transcriptional control mechanism, later extended by the finding that HTLV-I tat-I transactivates through the same region.","evidence":"Triplex oligonucleotide targeting of promoter combined with EMSA, nuclear run-on assays in lymphocytes, and promoter-CAT reporter deletion mapping","pmids":["2062658","3030566"],"confidence":"High","gaps":["Trans-acting factors beyond NF-κB not identified","Chromatin-level regulation unknown","No in vivo validation of promoter elements"]},{"year":1994,"claim":"Demonstration that Jak1 associates with IL-2Rβ and Jak3 with γc, with both required for IL-2 signaling, defined the proximal kinase cascade downstream of the receptor complex that CD25 assembly enables.","evidence":"Co-immunoprecipitation and reconstitution in Jak3-negative fibroblasts bearing IL-2R subunits","pmids":["7973659"],"confidence":"High","gaps":["Order of Jak activation unclear","STAT substrate specificity not fully delineated","How CD25 presence vs absence alters Jak activation not resolved"]},{"year":2002,"claim":"Discovery that SATB1 recruits NURD HDAC and ACF1/ISWI nucleosome-remodeling complexes to the IL2RA locus, with ectopic IL2RA expression in SATB1-null thymocytes, revealed that chromatin architecture actively represses IL2RA transcription in non-activated cells.","evidence":"ChIP for histone acetylation, nucleosome positioning assays, SATB1 knockout mice","pmids":["12374985"],"confidence":"High","gaps":["Interplay between SATB1 repression and NF-κB activation not defined","Enhancer architecture not mapped","Whether other locus-specific repressors exist was unknown"]},{"year":2004,"claim":"Trafficking studies resolved that CD25 follows a clathrin-independent endocytic pathway and recycles to the surface, while IL-2Rβ/γc are ubiquitinated and degraded, explaining how CD25 is maintained for sustained IL-2 sensing even as signaling chains are turned over.","evidence":"Endocytosis assays, subcellular fractionation, ubiquitination analysis","pmids":["15645712"],"confidence":"Medium","gaps":["Molecular sorting signals on CD25 that direct recycling not identified","Recycling kinetics not quantified in vivo","Relationship to lipid raft localization not established"]},{"year":2005,"claim":"The 2.3 Å crystal structure of the quaternary IL-2/IL-2Rα/IL-2Rβ/γc complex revealed that CD25 binding to IL-2 allosterically stabilizes the IL-2Rβ-binding surface and that γc docking uses degenerate contacts, providing the structural basis for high-affinity receptor assembly and explaining X-SCID mutations.","evidence":"X-ray crystallography of the full ectodomain quaternary complex","pmids":["16293754"],"confidence":"High","gaps":["Transmembrane and intracellular domain organization unknown","How structural changes propagate to Jak activation not resolved","No dynamics information from static crystal"]},{"year":2009,"claim":"MMP-9 was identified as the protease responsible for shedding membrane CD25 as soluble CD25, validated by MMP-9 knockout, pharmacologic inhibition, and direct enzyme treatment, establishing a mechanism for the well-known soluble IL-2Rα found in serum.","evidence":"MMP-9 knockout mice, doxycycline inhibition, in situ zymography, Western blot of CD25 in corneal epithelial cells","pmids":["19878594"],"confidence":"High","gaps":["Whether MMP-9 is the sole sheddase on immune cells not confirmed","Cleavage site on CD25 not mapped","Functional consequence of sCD25 on IL-2 signaling not defined"]},{"year":2009,"claim":"Disease-associated IL2RA polymorphisms were shown to regulate CD25 surface protein levels in a cell-type-specific manner (confirmed by allele-specific expression), mechanistically linking autoimmune risk variants to quantitative differences in IL-2 receptor expression rather than coding changes.","evidence":"Polychromatic flow cytometry for CD25 across immune subsets, genotype-stratified analysis, allele-specific expression","pmids":["19701192"],"confidence":"High","gaps":["Causal regulatory variant not pinpointed","Epigenomic mechanism of cell-type specificity unknown","Whether variants alter enhancer–promoter contacts not tested"]},{"year":2013,"claim":"A homozygous IL2RA null patient demonstrated that CD25 is essential for immune homeostasis: its loss causes pronounced CD8+ T-cell lymphoproliferation with STAT5-activated tissue-infiltrating CD8+ cells and impaired antigen-specific responses, while Tregs retain residual IL-2 responsiveness.","evidence":"Immunological phenotyping of IL2RA-null patient with flow cytometry, STAT5 phosphorylation, antigen-specific assays, and tissue biopsy","pmids":["23416241"],"confidence":"High","gaps":["Whether residual Treg function is mediated by intermediate-affinity IL-2R or alternative cytokines unclear","Only one patient studied at molecular depth","Mechanism of preferential CD8 hyperactivation not explained"]},{"year":2017,"claim":"CRISPR-Cas9 deletion of individual STAT5 binding sites within the Il2ra superenhancer each independently reduced IL-2-induced Il2ra expression, establishing that superenhancer elements are non-redundant and that STAT5-mediated chromatin looping is the sustained-phase transcriptional mechanism for IL2RA.","evidence":"ChIA-PET chromatin interaction mapping, CRISPR-Cas9 deletion of superenhancer elements in mice, ChIP-seq for STAT5","pmids":["29078395"],"confidence":"High","gaps":["How superenhancer integrates with the early TCR/Src-dependent phase not resolved","Whether human IL2RA superenhancer has identical architecture not tested","Contribution of individual STAT5 sites to Treg vs effector T cell expression not defined"]},{"year":2020,"claim":"IL2RA was shown to cell-autonomously promote AML cell proliferation, block differentiation, and maintain leukemic stem cell properties—a non-immune function validated by genetic knockdown and antibody inhibition in two mouse AML models—expanding CD25's role beyond immune regulation.","evidence":"shRNA knockdown, overexpression, and anti-CD25 antibody in human AML cells, primary patient samples, and two mouse AML models","pmids":["32873636"],"confidence":"High","gaps":["Downstream signaling pathway in AML cells not fully characterized","Whether AML CD25 signals through canonical Jak/STAT5 or alternative pathways unknown","Whether sCD25 shedding contributes to AML phenotype not tested"]},{"year":2021,"claim":"Bach2 was identified as a direct transcriptional repressor of CD25 in Tregs, with Bach2 deficiency upregulating CD25 and IL-2R signaling to partially compensate for poor Treg survival; this established a second chromatin-level repressive mechanism complementary to SATB1.","evidence":"Bach2 conditional knockout in Tregs, ChIP for Bach2 at Il2ra locus, flow cytometry, Tfr and GC analysis","pmids":["33979619"],"confidence":"High","gaps":["Whether Bach2 and SATB1 operate on the same or distinct regulatory elements not determined","Molecular interplay between Bach2 repression and STAT5 superenhancer activation not resolved"]},{"year":2023,"claim":"Tumor-specific CD8+ T cells co-expressing CD25 and PD-1 depend on autocrine IL-2–CD25 signaling for anti-PD-1 responsiveness, and IL-2Rα-biased agonists synergize with checkpoint blockade, establishing CD25 as a critical node in antitumor immunity.","evidence":"Comparison of IL-2 variants (IL-2Rα-biased vs IL-2Rβγ-biased) in mouse tumor models, autocrine IL-2 blockade, anti-PD-1 combination, human patient correlation","pmids":["37550516"],"confidence":"High","gaps":["Mechanism by which autocrine IL-2 is produced by TSTs not defined","Whether CD25-high TSTs represent a distinct differentiation state or activation state not resolved","Translation to human clinical anti-PD-1 settings not validated"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for full-length receptor transmembrane signaling, the identity of sorting signals directing CD25 recycling, how disease-associated non-coding variants alter superenhancer architecture cell-type-specifically, and the signaling pathway through which CD25 drives AML stem cell properties.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length IL-2R structural model including transmembrane/intracellular domains","CD25 recycling sorting signal not mapped","Causal autoimmune-risk variant–enhancer interactions not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,3,14,17]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,4,13,15]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[15]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,8,9,12,18,22,25,26]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,8,14,17,20,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[16,18,19,24]}],"complexes":["IL-2 receptor (IL-2Rα/IL-2Rβ/γc)"],"partners":["IL2RB","IL2RG","IL2","JAK1","JAK3","STAT5A","SATB1","BACH2"],"other_free_text":[]},"mechanistic_narrative":"IL2RA (CD25) encodes the alpha chain of the interleukin-2 receptor, which assembles with IL-2Rβ and the common γ-chain to form the high-affinity IL-2 receptor quaternary complex; the 2.3 Å crystal structure shows that CD25 binding to IL-2 stabilizes a secondary surface for IL-2Rβ recruitment and subsequent γc docking, enabling Jak1/Jak3–STAT5 signaling [PMID:16293754, PMID:7973659]. Transcription of IL2RA is activated in two phases—an early TCR/Src-kinase-dependent phase and a sustained JAK3/STAT5-dependent phase operating through non-redundant STAT5-bound superenhancer elements with chromatin looping—and is repressed by SATB1-recruited HDAC/nucleosome-remodeling complexes and by Bach2 [PMID:29078395, PMID:12374985, PMID:33979619, PMID:27936140]. After internalization via a clathrin-independent pathway, CD25 recycles to the plasma membrane while the β and γ chains are ubiquitinated and degraded, and membrane CD25 can be proteolytically shed as soluble CD25 by MMP-9 [PMID:15645712, PMID:19878594]. Homozygous loss-of-function IL2RA mutations in humans cause immune dysregulation with CD8+ T-cell lymphoproliferation and Treg dysfunction, and in AML, IL2RA cell-autonomously promotes proliferation, blocks differentiation, and sustains leukemic stem cell properties [PMID:23416241, PMID:32873636]."},"prefetch_data":{"uniprot":{"accession":"P01589","full_name":"Interleukin-2 receptor subunit alpha","aliases":["TAC antigen","p55"],"length_aa":272,"mass_kda":30.8,"function":"Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P01589/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IL2RA","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IL2RA","total_profiled":1310},"omim":[{"mim_id":"619935","title":"IMMUNODEFICIENCY 106, SUSCEPTIBILITY TO VIRAL INFECTIONS; IMD106","url":"https://www.omim.org/entry/619935"},{"mim_id":"617685","title":"CADHERIN 26; CDH26","url":"https://www.omim.org/entry/617685"},{"mim_id":"616834","title":"MICROCEPHALY, CONGENITAL CATARACT, AND PSORIASIFORM DERMATITIS; MCCPD","url":"https://www.omim.org/entry/616834"},{"mim_id":"616100","title":"IMMUNE DYSREGULATION WITH AUTOIMMUNITY, IMMUNODEFICIENCY, AND LYMPHOPROLIFERATION; IDAIL","url":"https://www.omim.org/entry/616100"},{"mim_id":"615648","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 3; NLRC3","url":"https://www.omim.org/entry/615648"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":17.5},{"tissue":"lymphoid tissue","ntpm":16.7},{"tissue":"urinary bladder","ntpm":10.1}],"url":"https://www.proteinatlas.org/search/IL2RA"},"hgnc":{"alias_symbol":["CD25"],"prev_symbol":["IL2R","IDDM10"]},"alphafold":{"accession":"P01589","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01589","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01589-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01589-F1-predicted_aligned_error_v6.png","plddt_mean":72.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IL2RA","jax_strain_url":"https://www.jax.org/strain/search?query=IL2RA"},"sequence":{"accession":"P01589","fasta_url":"https://rest.uniprot.org/uniprotkb/P01589.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01589/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01589"}},"corpus_meta":[{"pmid":"14676299","id":"PMC_14676299","title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14676299","citation_count":3776,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11812990","id":"PMC_11812990","title":"Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.","date":"2002","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11812990","citation_count":1313,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17277105","id":"PMC_17277105","title":"IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17277105","citation_count":499,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11740498","id":"PMC_11740498","title":"Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo.","date":"2001","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11740498","citation_count":486,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11298337","id":"PMC_11298337","title":"Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11298337","citation_count":371,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17056509","id":"PMC_17056509","title":"Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17056509","citation_count":369,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11591746","id":"PMC_11591746","title":"Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11591746","citation_count":335,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12163566","id":"PMC_12163566","title":"Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes.","date":"2002","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12163566","citation_count":300,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12893750","id":"PMC_12893750","title":"Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12893750","citation_count":292,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12023351","id":"PMC_12023351","title":"Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12023351","citation_count":286,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15585848","id":"PMC_15585848","title":"CD25- T cells generate CD25+Foxp3+ regulatory T cells by peripheral expansion.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15585848","citation_count":279,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15613550","id":"PMC_15613550","title":"CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15613550","citation_count":240,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19701192","id":"PMC_19701192","title":"Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19701192","citation_count":226,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19098714","id":"PMC_19098714","title":"miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA.","date":"2008","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/19098714","citation_count":225,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2062658","id":"PMC_2062658","title":"Oligonucleotide inhibition of IL2R alpha mRNA transcription by promoter region collinear triplex formation in lymphocytes.","date":"1991","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2062658","citation_count":188,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17563918","id":"PMC_17563918","title":"Expansion and activation of CD4(+)CD25(+) regulatory T cells in Heligmosomoides polygyrus infection.","date":"2007","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17563918","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15753306","id":"PMC_15753306","title":"Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15753306","citation_count":187,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16709816","id":"PMC_16709816","title":"CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16709816","citation_count":179,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28698369","id":"PMC_28698369","title":"A distinct subpopulation of CD25- T-follicular regulatory cells localizes in the germinal centers.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28698369","citation_count":167,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23416241","id":"PMC_23416241","title":"Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity.","date":"2013","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/23416241","citation_count":164,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25278028","id":"PMC_25278028","title":"Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells.","date":"2014","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25278028","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17311282","id":"PMC_17311282","title":"The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road.","date":"2007","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17311282","citation_count":127,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18650830","id":"PMC_18650830","title":"Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians.","date":"2008","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18650830","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19752032","id":"PMC_19752032","title":"Helminth infection can reduce insulitis and type 1 diabetes through CD25- and IL-10-independent mechanisms.","date":"2009","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19752032","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11591749","id":"PMC_11591749","title":"CD4(+)CD25(+) T cells facilitate the induction of T cell anergy.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11591749","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24412607","id":"PMC_24412607","title":"Reduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms.","date":"2014","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/24412607","citation_count":96,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37516849","id":"PMC_37516849","title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37516849","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14515264","id":"PMC_14515264","title":"Functional CD25- and CD25+ mucosal regulatory T cells are induced in gut-draining lymphoid tissue within 48 h after oral antigen application.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/14515264","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29078395","id":"PMC_29078395","title":"STAT5-mediated chromatin interactions in superenhancers activate IL-2 highly inducible genes: Functional dissection of the Il2ra gene locus.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/29078395","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19116909","id":"PMC_19116909","title":"Association of the IL2RA/CD25 gene with juvenile idiopathic arthritis.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19116909","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25295619","id":"PMC_25295619","title":"Central muscarinic cholinergic activation alters interaction between splenic dendritic cell and CD4+CD25- T cells in experimental colitis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25295619","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23300563","id":"PMC_23300563","title":"HSP70 enhances immunosuppressive function of CD4(+)CD25(+)FoxP3(+) T regulatory cells and cytotoxicity in CD4(+)CD25(-) T cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23300563","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36082452","id":"PMC_36082452","title":"CD25: A potential tumor therapeutic target.","date":"2022","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36082452","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17395754","id":"PMC_17395754","title":"Toward further mapping of the association between the IL2RA locus and type 1 diabetes.","date":"2007","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/17395754","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18855921","id":"PMC_18855921","title":"Ex vivo expansion of CD4(+)CD25(+) T regulatory cells for immunosuppressive therapy.","date":"2009","source":"Cytometry. Part A : the journal of the International Society for Analytical Cytology","url":"https://pubmed.ncbi.nlm.nih.gov/18855921","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12204972","id":"PMC_12204972","title":"CD4(+) CD25(+) T-cell production in healthy humans and in patients with thymic hypoplasia.","date":"2002","source":"Clinical and diagnostic laboratory immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12204972","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15128798","id":"PMC_15128798","title":"Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15128798","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17372588","id":"PMC_17372588","title":"Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells.","date":"2007","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17372588","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8496611","id":"PMC_8496611","title":"Role of CD25+ and CD25-T cells in acute HIV infection in vitro.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8496611","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37550516","id":"PMC_37550516","title":"IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells.","date":"2023","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37550516","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19265545","id":"PMC_19265545","title":"Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis.","date":"2009","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19265545","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9215668","id":"PMC_9215668","title":"Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11-q11.","date":"1997","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9215668","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30858199","id":"PMC_30858199","title":"TCR Affinity Biases Th Cell Differentiation by Regulating CD25, Eef1e1, and Gbp2.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30858199","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11781238","id":"PMC_11781238","title":"CD4(+)CD25(+) T-cell development is regulated by at least 2 distinct mechanisms.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11781238","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14679000","id":"PMC_14679000","title":"Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14679000","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27936140","id":"PMC_27936140","title":"Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27936140","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30578871","id":"PMC_30578871","title":"IFN-γ and CD25 drive distinct pathologic features during hemophagocytic lymphohistiocytosis.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30578871","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19231135","id":"PMC_19231135","title":"Variation in the IL7RA and IL2RA genes in German multiple sclerosis patients.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19231135","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3102753","id":"PMC_3102753","title":"Impaired expression of interleukin-2 receptor (IL2R) in the immunosuppressed burned patient: reversal by exogenous IL2.","date":"1987","source":"The Journal of trauma","url":"https://pubmed.ncbi.nlm.nih.gov/3102753","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15027897","id":"PMC_15027897","title":"CD4+ CD25+ Treg: divide and rule?","date":"2004","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15027897","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16368522","id":"PMC_16368522","title":"Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16368522","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16547222","id":"PMC_16547222","title":"Cutting edge: IL-4-induced protection of CD4+CD25- Th cells from CD4+CD25+ regulatory T cell-mediated suppression.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16547222","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2570038","id":"PMC_2570038","title":"Circulating human T and B lymphocytes express the p55 interleukin-2 receptor molecule (TAC, CD25).","date":"1989","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/2570038","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17911604","id":"PMC_17911604","title":"Enhanced engagement of CTLA-4 induces antigen-specific CD4+CD25+Foxp3+ and CD4+CD25- TGF-beta 1+ adaptive regulatory T cells.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17911604","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20179739","id":"PMC_20179739","title":"Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20179739","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24662004","id":"PMC_24662004","title":"New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids.","date":"2014","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/24662004","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26494229","id":"PMC_26494229","title":"Expansion of CD25+ Innate Lymphoid Cells Reduces Atherosclerosis.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26494229","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25060689","id":"PMC_25060689","title":"Leptin modulates autophagy in human CD4+CD25- conventional T cells.","date":"2014","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/25060689","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15645712","id":"PMC_15645712","title":"Clathrin-lndependent endocytosis and signalling of interleukin 2 receptors IL-2R endocytosis and signalling.","date":"2004","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15645712","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31288845","id":"PMC_31288845","title":"Blockade of TGF-β signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25-Foxp3+ T cells.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31288845","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19180473","id":"PMC_19180473","title":"Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.","date":"2009","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19180473","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23827156","id":"PMC_23827156","title":"Effects of estrogen on CD4(+) CD25(+) regulatory T cell in peripheral blood during pregnancy.","date":"2013","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23827156","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23529819","id":"PMC_23529819","title":"Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis.","date":"2013","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/23529819","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29872084","id":"PMC_29872084","title":"Regulation of CD4+CD8-CD25+ and CD4+CD8+CD25+ T cells by gut microbiota in chicken.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29872084","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23665004","id":"PMC_23665004","title":"Avian CD4(+)CD25(+) regulatory T cells: properties and therapeutic applications.","date":"2013","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23665004","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19878594","id":"PMC_19878594","title":"Cleavage of functional IL-2 receptor alpha chain (CD25) from murine corneal and conjunctival epithelia by MMP-9.","date":"2009","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19878594","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25193380","id":"PMC_25193380","title":"Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.","date":"2014","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25193380","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17244157","id":"PMC_17244157","title":"CD4+ CD25+ [corrected] regulatory T cells render naive CD4+ CD25- T cells anergic and suppressive.","date":"2007","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17244157","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29330114","id":"PMC_29330114","title":"Human CD4+ CD25+ CD127hi cells and the Th1/Th2 phenotype.","date":"2018","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/29330114","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30513621","id":"PMC_30513621","title":"Reduced Corneal Innervation in the CD25 Null Model of Sjögren Syndrome.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30513621","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24768797","id":"PMC_24768797","title":"Daclizumab (anti-CD25) in multiple sclerosis.","date":"2014","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24768797","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17374393","id":"PMC_17374393","title":"Neuropilin 1 and CD25 co-regulation during early murine thymic differentiation.","date":"2007","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17374393","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15681750","id":"PMC_15681750","title":"CD4(+) CD25(+) regulatory T cell selection.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15681750","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36706593","id":"PMC_36706593","title":"Dendritic cell-expressed IDO alleviates atherosclerosis by expanding CD4+CD25+Foxp3+Tregs through IDO-Kyn-AHR axis.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36706593","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10037026","id":"PMC_10037026","title":"Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.","date":"1999","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/10037026","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19956099","id":"PMC_19956099","title":"The type I diabetes association of the IL2RA locus.","date":"2009","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19956099","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20515837","id":"PMC_20515837","title":"CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies.","date":"2010","source":"Frontiers in bioscience (Scholar edition)","url":"https://pubmed.ncbi.nlm.nih.gov/20515837","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23230342","id":"PMC_23230342","title":"Trichinella spiralis infection suppressed gut inflammation with CD4(+)CD25(+)Foxp3(+) T cell recruitment.","date":"2012","source":"The Korean journal of parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/23230342","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26765264","id":"PMC_26765264","title":"The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells.","date":"2016","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26765264","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27156107","id":"PMC_27156107","title":"CD4(+)CD25(+)CD127(-) and CD4(+)CD25(+)Foxp3(+) Regulatory T Cell Subsets in Mediating Autoimmune Reactivity in Systemic Lupus Erythematosus Patients.","date":"2016","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/27156107","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15067325","id":"PMC_15067325","title":"DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.","date":"2004","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15067325","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18440785","id":"PMC_18440785","title":"Defective functions of circulating CD4+CD25+ and CD4+CD25- T cells in patients with chronic ordinary urticaria.","date":"2008","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/18440785","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33979619","id":"PMC_33979619","title":"Bach2 attenuates IL-2R signaling to control Treg homeostasis and Tfr development.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33979619","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32873636","id":"PMC_32873636","title":"IL2RA Promotes Aggressiveness and Stem Cell-Related Properties of Acute Myeloid Leukemia.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32873636","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32718891","id":"PMC_32718891","title":"MSCs-released TGFβ1 generate CD4+CD25+Foxp3+ in T-reg cells of human SLE PBMC.","date":"2020","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/32718891","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12121224","id":"PMC_12121224","title":"Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction.","date":"2002","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12121224","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29648897","id":"PMC_29648897","title":"Meta-analysis of the association of IL2RA polymorphisms rs2104286 and rs12722489 with multiple sclerosis risk.","date":"2018","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/29648897","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19309551","id":"PMC_19309551","title":"CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma.","date":"2009","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19309551","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22197557","id":"PMC_22197557","title":"FAS/FAS-L dependent killing of activated human monocytes and macrophages by CD4+CD25- responder T cells, but not CD4+CD25+ regulatory T cells.","date":"2011","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/22197557","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22012429","id":"PMC_22012429","title":"The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis.","date":"2011","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/22012429","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31354726","id":"PMC_31354726","title":"Generation of Foxp3+CD25- Regulatory T-Cell Precursors Requires c-Rel and IκBNS.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31354726","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28866095","id":"PMC_28866095","title":"Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28866095","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16146782","id":"PMC_16146782","title":"Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2.","date":"2006","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/16146782","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28935468","id":"PMC_28935468","title":"Function and regulation of LAG3 on CD4+CD25- T cells in non-small cell lung cancer.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/28935468","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30968455","id":"PMC_30968455","title":"Allergen-specific immunotherapy enhances CD8+  CD25+  CD137+ regulatory T cells and decreases nasal nitric oxide.","date":"2019","source":"Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30968455","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18606654","id":"PMC_18606654","title":"FOXP3 induced by CD28/B7 interaction regulates CD25 and anergic phenotype in human CD4+CD25- T lymphocytes.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18606654","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31279323","id":"PMC_31279323","title":"Effect of IL2RA and IL2RB gene polymorphisms on lung cancer risk.","date":"2019","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31279323","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29979892","id":"PMC_29979892","title":"Genetic variant association of PTPN22, CTLA4, IL2RA, as well as HLA frequencies in susceptibility to alopecia areata.","date":"2018","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/29979892","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27664932","id":"PMC_27664932","title":"MicroRNA 182 inhibits CD4+CD25+Foxp3+ Treg differentiation in experimental autoimmune encephalomyelitis.","date":"2016","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/27664932","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37731506","id":"PMC_37731506","title":"Causal relationships between CD25 on immune cells and hip osteoarthritis.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37731506","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23128233","id":"PMC_23128233","title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23128233","citation_count":3725,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21833088","id":"PMC_21833088","title":"Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21833088","citation_count":2101,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21102463","id":"PMC_21102463","title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21102463","citation_count":2036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24390342","id":"PMC_24390342","title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24390342","citation_count":1778,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19430480","id":"PMC_19430480","title":"Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19430480","citation_count":1382,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17660530","id":"PMC_17660530","title":"Risk alleles for multiple sclerosis identified by a genomewide study.","date":"2007","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17660530","citation_count":1319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8072542","id":"PMC_8072542","title":"A genome-wide search for human type 1 diabetes susceptibility genes.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8072542","citation_count":1167,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20453842","id":"PMC_20453842","title":"Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20453842","citation_count":1018,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6090948","id":"PMC_6090948","title":"Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6090948","citation_count":936,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8493579","id":"PMC_8493579","title":"Human Sos1: a guanine nucleotide exchange factor for Ras that binds to GRB2.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/8493579","citation_count":772,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2785715","id":"PMC_2785715","title":"Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's.","date":"1989","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2785715","citation_count":750,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19264985","id":"PMC_19264985","title":"Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes.","date":"2009","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19264985","citation_count":747,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19525953","id":"PMC_19525953","title":"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19525953","citation_count":639,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20596022","id":"PMC_20596022","title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20596022","citation_count":621,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6090949","id":"PMC_6090949","title":"Molecular cloning of cDNA encoding human interleukin-2 receptor.","date":"1984","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/6090949","citation_count":608,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19073967","id":"PMC_19073967","title":"Shared and distinct genetic variants in type 1 diabetes and celiac disease.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19073967","citation_count":566,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2983318","id":"PMC_2983318","title":"Interleukin 2 regulates its own receptors.","date":"1985","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2983318","citation_count":546,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7973659","id":"PMC_7973659","title":"Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits.","date":"1994","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7973659","citation_count":540,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22446627","id":"PMC_22446627","title":"Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.","date":"2012","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22446627","citation_count":461,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3030566","id":"PMC_3030566","title":"Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I.","date":"1987","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3030566","citation_count":449,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19525955","id":"PMC_19525955","title":"Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19525955","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18978792","id":"PMC_18978792","title":"Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18978792","citation_count":415,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12374985","id":"PMC_12374985","title":"SATB1 targets chromatin remodelling to regulate genes over long distances.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12374985","citation_count":414,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16293754","id":"PMC_16293754","title":"Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16293754","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16955142","id":"PMC_16955142","title":"Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16955142","citation_count":392,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15972448","id":"PMC_15972448","title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15972448","citation_count":377,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8072544","id":"PMC_8072544","title":"Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8072544","citation_count":377,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49451,"output_tokens":4362,"usd":0.106892},"stage2":{"model":"claude-opus-4-6","input_tokens":7898,"output_tokens":3956,"usd":0.207585},"total_usd":0.692999,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62233,"output_tokens":7561,"usd":0.150057},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11597,"output_tokens":3773,"usd":0.228465}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"The IL2RA promoter region contains a κB enhancer element (-266 to -256) and a serum response element (CArG box, -251 to -244) that are critical for transcriptional upregulation following T lymphocyte activation; triplex-forming oligonucleotides targeting this region selectively inhibited IL2RA mRNA transcription in intact lymphocytes.\",\n      \"method\": \"Electrophoretic mobility shift assay, restriction endonuclease inhibition, nuclear run-on transcription assay, oligonucleotide-mediated triplex formation in live lymphocytes\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal in vitro and cell-based assays with rigorous controls demonstrating sequence-specific effect on IL2RA transcription\",\n      \"pmids\": [\"2062658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In the IL-2 receptor system, Jak3 (pre-associated with IL-2Rγc) can unilaterally transphosphorylate Jak1 (pre-associated with IL-2Rβ), but not vice versa, indicating Jak3 activation precedes Jak1 activation; IL-2Rα (CD25) itself is not a direct JAK substrate, whereas IL-2Rβ is phosphorylated by both Jak1 and Jak3, and IL-2Rγc is phosphorylated only by Jak3.\",\n      \"method\": \"Baculovirus reconstitution of recombinant IL2R subunits and JAK kinases; in vitro kinase/transphosphorylation assays; co-expression with kinase-dead mutants\",\n      \"journal\": \"Leukemia & lymphoma\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with kinase-dead mutants and multiple substrate pairs, providing direct mechanistic evidence\",\n      \"pmids\": [\"10037026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-2Rα (CD25) localizes to membrane microdomains (lipid rafts), and its presence shifts IL-2R signaling from a Jak3-independent, anti-apoptotic intermediate-affinity mode (occurring in soluble membrane fractions) to a Jak3-dependent, high-affinity proliferative mode; TCR signaling induces CD25 expression that promotes this localization.\",\n      \"method\": \"Membrane fractionation, analysis of JAK3-dependent vs. JAK3-independent signaling in cells with or without CD25 expression; pharmacological inhibition studies\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic model supported by biochemical fractionation and inhibitor experiments from a single paper without full reconstitution\",\n      \"pmids\": [\"12121224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD4+CD25+ regulatory thymocytes suppress target T cells via a contact-dependent mechanism involving CTLA-4 and membrane TGF-β1, which together inhibit IL-2Rα (CD25) expression on target T cells, thereby blocking target cell responsiveness to IL-2.\",\n      \"method\": \"Blocking antibody experiments (anti-CTLA-4, anti-TGF-β1), co-culture suppression assays, flow cytometry for CD25 restoration on target cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal antibody blockade with defined phenotypic readout (CD25 re-expression on target cells), replicated in CD8+CD25+ thymocytes\",\n      \"pmids\": [\"12163566\", \"12893750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-2Rα (CD25) undergoes clathrin-independent endocytosis; after internalization, the α-chain (CD25) recycles to the plasma membrane while the β and γ chains are targeted to late endosomes/lysosomes and degraded, a process involving ubiquitination of the receptor as a sorting signal.\",\n      \"method\": \"Endocytic pathway analysis, subcellular fractionation, receptor trafficking assays, ubiquitination studies\",\n      \"journal\": \"Current topics in microbiology and immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct trafficking experiments with mechanistic detail, single lab review compilation of original data\",\n      \"pmids\": [\"15645712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"IL-2 signaling through CD25 (IL-2Rα) is required for the development and maintenance of CD4+CD25+ regulatory T cells; IL-2 deficiency or neutralization abolishes TGF-β-mediated induction of Foxp3 and CD25 in naive T cells, while other γ-chain cytokines (IL-4, IL-7, IL-15) can sustain but not initiate Foxp3 expression.\",\n      \"method\": \"Antibody neutralization of IL-2, IL-2-deficient mouse experiments, cytokine substitution assays\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (IL-2 KO mice) plus pharmacological (neutralizing antibody) approaches, replicated across multiple experimental conditions\",\n      \"pmids\": [\"17277105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MMP-9 proteolytically cleaves functional IL-2Rα (CD25) from corneal and conjunctival epithelial cells into soluble form; desiccating stress upregulates MMP-9, which reduces membrane CD25 and increases soluble CD25 in tears, and this cleavage is prevented by MMP-9 inhibitors or MMP-9 knockout.\",\n      \"method\": \"MMP-9 knockout mice, topical MMP inhibitor (doxycycline), immunofluorescence, Western blot, in vitro MMP-9 treatment of cultured corneal epithelial cells, immunobead assay for soluble CD25 in tears\",\n      \"journal\": \"Journal of inflammation (London, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — genetic KO, pharmacological inhibition, and direct in vitro enzyme treatment with multiple orthogonal readouts all converge on MMP-9 as the cleavage enzyme\",\n      \"pmids\": [\"19878594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Differences in surface IL-2Rα (CD25) protein expression on specific immune cell types correlate with distinct IL2RA haplotypes associated with type 1 diabetes and multiple sclerosis, confirmed by allele-specific expression at the RNA level, indicating that disease-associated variants regulate cell-type-specific IL2RA expression.\",\n      \"method\": \"Polychromatic flow cytometry, allele-specific expression (ASE) analysis, genotype-selectable human bioresource\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal methods (protein by flow cytometry and RNA by ASE) in a large genotype-selectable cohort\",\n      \"pmids\": [\"19701192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TCR signal strength directly regulates the duration of CD25 (IL-2Rα) expression on naive CD4+ T cells: high-affinity TCR interactions sustain CD25 expression longer, keeping cells responsive to IL-2-driven Th1 differentiation, while low-affinity interactions lead to faster CD25 loss and bias toward Tfh differentiation.\",\n      \"method\": \"Selective kinase inhibitors (PP2 for Src kinase, WHI-P131 for JAK3), STAT5 phosphorylation assays, flow cytometry for CD25 dynamics in human peripheral blood lymphocytes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of distinct signaling stages with time-resolved CD25 expression in primary human T cells, single lab\",\n      \"pmids\": [\"27936140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-2-activated STAT5 binds a superenhancer at the Il2ra locus and induces new chromatin interactions (looping) within the superenhancer; CRISPR-Cas9 deletion of individual STAT5 binding sites within the Il2ra superenhancer each reduced STAT5 binding and decreased IL-2-induced Il2ra expression, demonstrating that all elements are non-redundant and cooperate to achieve normal IL2RA induction.\",\n      \"method\": \"ChIA-PET chromatin interaction sequencing, CRISPR-Cas9 mutagenesis of superenhancer elements in mice, ChIP-seq for STAT5, quantitative Il2ra expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — CRISPR genome editing combined with chromatin interaction mapping and ChIP-seq; multiple mutant alleles tested in vivo\",\n      \"pmids\": [\"29078395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"An MS-associated polymorphism in the IL2RA gene specifically increases IL-2 responsiveness of naive TH cells, raising their propensity to develop into GM-CSF-producing memory TH cells; the IL2RA variant thus mechanistically links IL-2R signaling to neuroinflammation via enhanced GM-CSF production.\",\n      \"method\": \"Functional assays of IL-2 responsiveness and GM-CSF production in genotyped human TH cells stratified by IL2RA haplotype\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional readout (cytokine production) stratified by IL2RA genotype in primary human cells, single lab\",\n      \"pmids\": [\"25278028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD25 expression on hyperactivated CD8+ T cells enables excessive IL-2 consumption, which drives the immunological (lymphocyte hyperactivation) but not hematological features of hemophagocytic lymphohistiocytosis (HLH); the hematological features are instead fully dependent on IFN-γ production, establishing a dichotomous mechanism.\",\n      \"method\": \"Genetic elimination of CD25 or IFN-γ production in Prf1 KO mice infected with LCMV; assessment of hematologic, immunologic, and physiologic disease parameters\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis using mouse KO models with multiple defined disease readouts, clearly separating two mechanistic pathways\",\n      \"pmids\": [\"30578871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The transcription factor Bach2 directly represses CD25 (IL-2Rα) expression in regulatory T cells, thereby attenuating IL-2R signaling; Bach2 deficiency in resting Tregs leads to upregulated CD25/IL-2R signaling that partially compensates for their impaired survival, and Bach2 also suppresses CD25 in T follicular regulatory (Tfr) cells to control GC responses.\",\n      \"method\": \"Bach2 conditional knockout in Tregs, ChIP or reporter assays for Bach2 binding to CD25 locus, flow cytometry for CD25 and pSTAT5, Tfr cell enumeration and GC analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with defined molecular readouts (CD25 upregulation, IL-2R signaling, Tfr differentiation) in a clean conditional KO model\",\n      \"pmids\": [\"33979619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IL-2Rα (CD25)-biased IL-2 agonists selectively expand tumor-infiltrating CD25+CD8+ T cells that co-express PD-1; tumor-specific CD8+ T cells upregulate CD25 and depend on autocrine IL-2–CD25 signaling for their activation by anti-PD-1 therapy, and IL-2Rα-biased agonists (but not IL-2Rβγ-biased agonists) synergize with anti-PD-1 to eradicate established tumors.\",\n      \"method\": \"In vitro IL-2 stimulation assays, mouse tumor models with IL-2 variants, flow cytometry of tumor-infiltrating lymphocytes, PD-1+CD25+ T cell functional assays, anti-PD-1 combination studies\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mouse tumor models with mechanistic dissection of CD25 role in T cell activation, corroborated by human cancer patient data\",\n      \"pmids\": [\"37550516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL2RA promotes AML cell proliferation and inhibits apoptosis; genetic manipulation and antibody-mediated inhibition of IL2RA in human AML lines, mouse AML models, and primary patient samples showed that IL2RA is required for leukemogenesis, inhibits differentiation, and promotes leukemic stem cell properties, acting through cell-cycle and cell-survival/apoptosis pathways.\",\n      \"method\": \"Genetic overexpression and knockdown of IL2RA, anti-IL2RA antibody treatment, two mouse AML models, primary patient samples, flow cytometry, signaling pathway analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological manipulations across human cell lines, mouse models, and primary patient cells with defined phenotypic and pathway readouts\",\n      \"pmids\": [\"32873636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FOXP3, induced by CD28/B7 interaction via PI3K/Akt pathways in human CD4+CD25- T cells, is directly recruited to the CD25 (IL2RA) promoter and regulates CD25 expression; FOXP3 expression correlates with transient CD25 upregulation and T cell unresponsiveness, demonstrating a FOXP3→CD25 regulatory axis.\",\n      \"method\": \"ChIP for FOXP3 at CD25/IL-2/CTLA4 promoters, cyclosporin A and PI3K inhibitor experiments, CD28 stimulation without TCR engagement, flow cytometry\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP demonstrating FOXP3 binding to IL2RA promoter plus pharmacological pathway dissection, multiple orthogonal methods\",\n      \"pmids\": [\"18606654\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL2RA (CD25) encodes the α-chain of the high-affinity IL-2 receptor, whose expression is transcriptionally controlled by NF-κB/CArG enhancers and STAT5-bound superenhancers with cooperative chromatin looping, while its surface levels are negatively regulated by Bach2 (which represses the CD25 locus) and positively by FOXP3 (recruited to the CD25 promoter downstream of CD28/PI3K-Akt signaling); CD25 localizes to lipid rafts to enable Jak3-dependent high-affinity IL-2 signaling (distinct from the Jak3-independent intermediate-affinity mode), is proteolytically shed by MMP-9 to generate soluble CD25, and undergoes clathrin-independent endocytosis with α-chain recycling while β/γ chains are ubiquitinated and degraded; functionally, CD25 is essential for regulatory T cell development and homeostasis, enables IL-2 consumption by activated CD8+ T cells to drive immunopathology, promotes AML leukemogenesis and stem cell properties, and its biased engagement by IL-2 agonists selectively activates tumor-infiltrating CD25+PD-1+ CD8+ T cells to enhance anti-tumor immunity.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract mechanistic discoveries only from KEEP papers about the canonical IL2RA protein (CD25, the IL-2 receptor alpha chain).\n\nAfter reviewing all papers, the key mechanistic papers to extract from are those describing direct experiments on IL2RA/CD25 protein function, structure, signaling, regulation, and binding.\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1984,\n      \"finding\": \"Molecular cloning of the human IL-2 receptor alpha chain (IL2RA/CD25) cDNA revealed a single gene producing two mRNAs with different polyadenylation signals, and an alternatively spliced form lacking 216 bases that cannot bind IL-2; the encoded protein was expressed in COS cells and shown to bind IL-2.\",\n      \"method\": \"cDNA cloning, sequencing, expression in COS cells, IL-2 binding assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original molecular cloning with direct expression and binding validation, foundational paper >900 citations\",\n      \"pmids\": [\"6090948\", \"6090949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"IL-2 itself upregulates cell-surface expression of its own receptor (Tac antigen/CD25) in an 8-10-fold enhancement of anti-Tac binding sites while simultaneously reducing high-affinity IL-2 binding sites; the magnitude of the proliferative response correlated with high-affinity IL-2 binding site density rather than CD25 (Tac) levels, demonstrating that IL-2–receptor interactions promote loss of IL-2 responsiveness.\",\n      \"method\": \"Radiolabeled monoclonal antibody binding assays, IL-2 binding competition, membrane proteolysis recovery assays, proliferation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal binding and functional assays, >500 citations, foundational study\",\n      \"pmids\": [\"2983318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"The IL2RA promoter contains regulatory elements between −327 and −265 that drive constitutive expression in HTLV-I-infected T cells; the HTLV-I transactivator protein (tat-I) activates IL2RA promoter constructs through a specific region (−267 to −265) in a cell-type-specific manner requiring additional cellular factors.\",\n      \"method\": \"5' deletion promoter-CAT reporter constructs, cotransfection with tat-I expression vector, cell-type specificity experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — deletion mapping with functional reporter assays, replicated across cell types, >400 citations\",\n      \"pmids\": [\"3030566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"The IL-2 receptor beta chain (IL-2Rβ, p70-75) was cloned; when co-expressed with IL-2Rα cDNA, the two chains together reconstitute a high-affinity IL-2 receptor, demonstrating that IL-2Rα and IL-2Rβ together form the high-affinity complex.\",\n      \"method\": \"cDNA cloning, co-expression of IL-2Rα and IL-2Rβ in T lymphoid cells, IL-2 binding assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution of high-affinity receptor by co-expression, >700 citations\",\n      \"pmids\": [\"2785715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"CD25 (IL-2Rα/Tac antigen) is detectable on 15–45% of circulating human T and B lymphocytes using a highly sensitive immunofluorescence procedure, revealing constitutive low-level CD25 expression on resting lymphocytes including CD4+ T cells, CD8+ T cells, and B cells.\",\n      \"method\": \"Highly sensitive indirect immunofluorescence with three different anti-CD25 antibodies, double-marker studies for lineage identification\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct localization/expression experiment, single lab but multiple antibodies and cell types\",\n      \"pmids\": [\"2570038\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"A triplex-forming oligonucleotide targeting the IL2RA promoter region (−273 to −246), spanning the κB enhancer and CArG box, selectively inhibited IL2RA mRNA transcription in intact lymphocytes for up to 12 hours after PHA stimulation, as confirmed by nuclear run-on assays, demonstrating that the κB and CArG elements are required for normal IL2RA transcriptional activation.\",\n      \"method\": \"Triplex oligonucleotide designed to IL2RA promoter, EMSA for binding specificity, restriction enzyme inhibition assay, nuclear run-on transcription assays in intact lymphocytes\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (EMSA, restriction protection, nuclear run-on) confirming promoter element function\",\n      \"pmids\": [\"2062658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CD25+ (activated) T cells are the principal producers of HIV in acutely infected PBMC cultures; elimination of the small CD25+ population (3–5%) before infection reduces p24 secretion by 99%, and killing CD25+ cells after infection virtually stops viral production and spread, while resting CD25− cells can be infected but only produce virus upon subsequent activation.\",\n      \"method\": \"Anti-CD25–ricin A chain immunotoxin (RFT5-dgA) selective depletion before/after HIV infection, p24 ELISA, coculture with H9 cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — selective depletion with immunotoxin, multiple experimental conditions, clear mechanistic readout\",\n      \"pmids\": [\"8496611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Jak1 and Jak3 are selectively and functionally associated with distinct IL-2R subunits: Jak1 associates with the serine-rich region of IL-2Rβ and Jak3 associates with the carboxyl-terminal region of IL-2Rγ; both associations are required for IL-2 signaling, and expression of Jak3 cDNA in Jak3-negative fibroblasts bearing reconstituted IL-2R conferred IL-2 responsiveness.\",\n      \"method\": \"Co-immunoprecipitation, reconstitution in Jak3-negative fibroblasts with IL-2R subunits and Jak3 cDNA, IL-2 stimulation and tyrosine phosphorylation assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution in heterologous cells plus co-IP, >500 citations, foundational JAK-STAT signaling paper\",\n      \"pmids\": [\"7973659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In the IL-2R signaling system, Jak3 can transphosphorylate a kinase-dead Jak1, but Jak1 cannot phosphorylate kinase-dead Jak3, suggesting Jak3 activation precedes Jak1; Jak3 phosphorylates both IL-2Rβ and IL-2Rγc, while Jak1 phosphorylates only IL-2Rβ; Jak3 activates STAT3 and STAT5 but not STAT1, whereas Jak1 activates STAT1, STAT3, and STAT5, revealing differential substrate specificity between the two kinases.\",\n      \"method\": \"Baculovirus-expressed recombinant Jak1, Jak3, and kinase-dead mutants; co-expression of IL-2R subunits; in vitro tyrosine phosphorylation assays; STAT phosphorylation analysis\",\n      \"journal\": \"Leukemia & lymphoma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with recombinant proteins and kinase-dead mutants, single study\",\n      \"pmids\": [\"10037026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD25 (IL-2Rα) suppressive function in human thymocytes is mediated by CTLA-4 and membrane TGF-β1 acting together to inhibit IL-2Rα chain (CD25) expression on target T cells; anti-CTLA-4 or anti-TGF-β1 alone partially inhibit suppression, but the combination completely blocks it and restores CD25 expression on target cells, thereby restoring IL-2 responsiveness.\",\n      \"method\": \"Mixed lymphocyte culture suppression assays with CD4+CD25+ human thymocytes, antibody blocking experiments (anti-CTLA-4, anti-TGF-β1), flow cytometry for CD25 expression on target cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal blocking experiments with multiple antibodies and clear mechanistic readout (CD25 re-expression on targets)\",\n      \"pmids\": [\"12163566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD25 (IL-2Rα) localization within membrane microdomains is proposed to switch IL-2R signaling: in the absence of CD25, IL-2R activation occurs in the soluble membrane fraction and promotes Jak3-independent, antiapoptotic signaling; when CD25 is induced by TCR signaling and localizes to microdomains with CD122, the high-affinity receptor complex activates Jak3 and shifts the balance toward proliferation versus activation-induced cell death.\",\n      \"method\": \"Review integrating published biochemical fractionation and signaling data; analysis of membrane microdomain distribution of CD25 and CD122\",\n      \"journal\": \"Immunology and cell biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — mechanistic model review without new primary experimental data\",\n      \"pmids\": [\"12121224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"SATB1 recruits the NURD histone deacetylase complex and the ACF1/ISWI nucleosome-remodeling complexes to a specific binding site in the IL-2Rα (IL2RA) locus, mediating deacetylation of histones over a large chromatin domain and regulating nucleosome positioning over 7 kilobases; in SATB1-null thymocytes, IL-2Rα is ectopically transcribed, demonstrating that SATB1 represses IL2RA through targeted chromatin remodeling.\",\n      \"method\": \"ChIP for histone acetylation, nucleosome positioning assays, SATB1 knockout mice (ectopic IL-2Rα transcription phenotype), co-recruitment of NURD/ACF1/ISWI complexes\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple chromatin assays plus genetic KO with clear phenotype, >400 citations\",\n      \"pmids\": [\"12374985\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD8+CD25+ human thymocytes suppress autologous CD25− T cell proliferation via a contact-dependent mechanism requiring CTLA-4 and membrane TGF-β1 acting together, and this suppression is mediated by inhibition of IL-2Rα (CD25) expression on target T cells—the same mechanism used by CD4+CD25+ regulatory thymocytes.\",\n      \"method\": \"Suppression assays with purified CD8+CD25+ thymocytes, antibody blocking (anti-CTLA-4 + anti-TGF-β1), flow cytometry for CD25 on target cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal blocking experiments confirming mechanism, orthogonal to prior CD4+CD25+ thymocyte study\",\n      \"pmids\": [\"12893750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IL-2R α-chain (CD25) endocytic trafficking follows a clathrin-independent pathway; after internalization, CD25/IL-2Rα recycles to the plasma membrane while IL-2Rβ and IL-2Rγ are targeted to late endosomes/lysosomes for degradation via ubiquitination as a sorting signal.\",\n      \"method\": \"Endocytosis assays, subcellular fractionation, trafficking studies distinguishing clathrin-dependent vs. independent routes, ubiquitination analysis\",\n      \"journal\": \"Current topics in microbiology and immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular trafficking experiments identifying differential fates of IL-2R chains\",\n      \"pmids\": [\"15645712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structure of the quaternary IL-2/IL-2Rα/IL-2Rβ/γc ectodomain complex at 2.3 Å resolution revealed that IL-2Rα binding to IL-2 stabilizes a secondary binding site that is presented to IL-2Rβ; γc is then recruited to the composite IL-2/IL-2Rβ surface through degenerate contacts consistent with its shared use by multiple cytokines; the structure provides a molecular rationale for X-SCID-associated loss-of-function mutations in γc.\",\n      \"method\": \"X-ray crystallography at 2.3 Å resolution of the quaternary ectodomain complex\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure of the complete quaternary complex, >400 citations\",\n      \"pmids\": [\"16293754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD25 (IL-2Rα) is expressed on corneal and conjunctival epithelial cells and is proteolytically cleaved to generate soluble CD25 in tears by matrix metalloproteinase 9 (MMP-9); desiccating stress increases MMP-9 activity and reduces membrane CD25 in the ocular surface epithelium; this cleavage is prevented by MMP-9 inhibition (doxycycline) and is absent in MMP-9 knockout mice, and confirmed by MMP-9 treatment of cultured corneal epithelial cells.\",\n      \"method\": \"MMP-9 knockout mice, topical MMP-9 inhibitor (doxycycline), in situ zymography, confocal immunofluorescence, Western blot of CD25 in epithelial lysates, immunobead assay for soluble CD25 in tears, MMP-9 treatment of human corneal epithelial cells\",\n      \"journal\": \"Journal of inflammation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO, pharmacologic inhibition, and direct enzyme treatment with multiple orthogonal readouts\",\n      \"pmids\": [\"19878594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Differences in surface IL2RA (CD25) protein expression on specific immune cell types (but not others) correlate with haplotypes in the IL2RA region associated with type 1 diabetes and multiple sclerosis; this gene-phenotype correlation was confirmed at the RNA level by allele-specific expression, demonstrating that disease-associated IL2RA variants functionally regulate CD25 protein levels in a cell-type-specific manner.\",\n      \"method\": \"Polychromatic flow cytometry for CD25 surface expression across immune cell types, genotyping of IL2RA haplotypes, allele-specific expression (ASE) analysis at RNA level\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — flow cytometry + ASE in large genotype-selectable biobank, two orthogonal methods confirming cell-type-specific regulation\",\n      \"pmids\": [\"19701192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In vitro evolution of IL-2 generated a 'superkine' (super-2) with increased affinity for IL-2Rβ that eliminates the functional requirement for CD25; crystal structures of the superkine in free and receptor-bound forms showed evolved mutations stabilize the IL-2Rβ binding helix into a CD25-bound-like conformation; the superkine recapitulates CD25 function by eliciting STAT5 phosphorylation and T cell proliferation independent of CD25 expression.\",\n      \"method\": \"In vitro evolution (yeast display), crystal structures of IL-2 superkine free and receptor-bound, molecular dynamics simulations, STAT5 phosphorylation assays, T cell proliferation assays, in vivo antitumor models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional reconstitution and mutagenesis-equivalent in vitro evolution, >460 citations\",\n      \"pmids\": [\"22446627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A patient with a novel homozygous IL2RA null mutation exhibited pronounced CD8+ T cell lymphoproliferation with activated CD8+STAT5+ T cells infiltrating tissues, impaired antigen-specific responses, and FOXP3+ Tregs that retained higher capacity to respond to IL-2 compared to other T cell subsets, demonstrating that CD25/IL-2Rα is required for normal immune homeostasis and its loss leads to disproportionate CD8+ hyperactivation despite residual Treg IL-2 responsiveness.\",\n      \"method\": \"Analysis of IL2RA null patient: flow cytometry, STAT5 phosphorylation assays, in vitro/in vivo antigen-specific response assays, skin biopsy immunohistochemistry, serum cytokine measurement\",\n      \"journal\": \"Clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — natural human loss-of-function mutation with comprehensive immunological phenotyping using multiple orthogonal methods\",\n      \"pmids\": [\"23416241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"An MS-associated IL2RA polymorphism (rs2104286) specifically increases IL-2 responsiveness of naive TH cells, measured by GM-CSF production; the variant regulates the propensity of naive TH cells to develop into GM-CSF-producing memory TH cells, mechanistically linking the IL2RA risk allele to increased neuroinflammatory TH cell function.\",\n      \"method\": \"Genotype-stratified analysis of human donor T cells; IL-2 stimulation assays; intracellular cytokine staining for GM-CSF; ex vivo differentiation assays from naive to memory TH cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional comparison of IL-2 responsiveness stratified by genotype with multiple T cell assays\",\n      \"pmids\": [\"25278028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD25 (IL-2Rα) expression on human peripheral blood T cells is regulated in two temporally distinct phases: an early Src kinase (TCR-associated)-dependent phase required for T cell competence and IL-2 responsiveness, and a later JAK3/STAT5-dependent phase that sustains high and prolonged CD25 expression to drive cell growth and proliferation; in competent CD25+ T cells bearing high-affinity IL-2R, IL-2 switches on a JAK3/STAT5 pathway that is constitutively JAK3-independent in quiescent cells.\",\n      \"method\": \"Selective kinase inhibitors (PP2 for Src, WHI-P131 for JAK3), flow cytometry for CD25 dynamics, STAT3/STAT5 phosphorylation assays (tyrosine phosphorylation), mitogen dose-response experiments in human peripheral blood lymphocytes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacologic dissection with selective inhibitors and multiple signaling readouts, single lab study\",\n      \"pmids\": [\"27936140\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IL-2-activated STAT5 binds to a superenhancer at the Il2ra locus and induces new chromatin looping interactions; CRISPR-Cas9 editing of three individual STAT5 binding sites within the Il2ra superenhancer in mice each decreased STAT5 binding and reduced IL-2-induced Il2ra expression, demonstrating that superenhancer elements are non-redundant and all required for normal IL2RA gene expression; STAT5-mediated chromatin looping preferentially regulates highly IL-2-inducible genes.\",\n      \"method\": \"ChIA-PET chromatin interaction sequencing, CRISPR-Cas9 deletion of superenhancer elements in mice, ChIP-seq for STAT5 binding, quantitative Il2ra mRNA expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — CRISPR-validated superenhancer elements combined with chromatin interaction mapping (ChIA-PET)\",\n      \"pmids\": [\"29078395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In a mouse model of hemophagocytic lymphohistiocytosis (HLH), CD25 expression on hyperactivated CD8+ T cells drives the immunological (but not hematologic) features of disease through excessive IL-2 consumption; genetic elimination of CD25 substantially corrected immunologic HLH features, while hematologic features were completely dependent on IFN-γ, revealing a dichotomous pathogenic mechanism.\",\n      \"method\": \"Prf1-knockout mouse model of HLH with genetic elimination of IFN-γ production or CD25 expression; assessment of hematologic, immunologic, and physiologic disease parameters\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in mouse model with clean dissection of two pathways using separate KO conditions\",\n      \"pmids\": [\"30578871\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"High-affinity TCR signaling sustains IL-2R (CD25) expression longer on naive T cells than low-affinity TCR interactions, directing them toward Th1/Th17 rather than Tfh differentiation; this TCR affinity effect on Th fate acts through direct regulation of CD25 and novel differentiation regulators (Eef1e1, Gbp2) in naive T cells, not through preferential T cell–dendritic cell interactions.\",\n      \"method\": \"Adoptive transfer of TCR transgenic T cells with defined affinity variants, flow cytometry for CD25 and Th subset markers post-infection, gene expression analysis (Eef1e1, Gbp2), DC subset interaction tracking\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo TCR affinity variants with multiple Th fate markers, single lab study\",\n      \"pmids\": [\"30858199\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL2RA promotes proliferation, cell-cycle activity, and inhibits apoptosis in AML cells; IL2RA inhibits differentiation and promotes leukemic stem cell properties; genetic knockdown or antibody-mediated inhibition of IL2RA reduces leukemogenesis in two genetically distinct mouse AML models while sparing normal hematopoietic cells, demonstrating a cell-autonomous oncogenic role for IL2RA in AML independent of its classical immune regulatory function.\",\n      \"method\": \"Genetic manipulation (shRNA knockdown, overexpression) and antibody inhibition of IL2RA in human AML cell lines and primary patient samples; two mouse AML models (genetic knockdown); flow cytometry for differentiation and stem cell markers; proliferation, apoptosis, and cell-cycle assays; drug synergy experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacologic loss-of-function approaches in human cells, primary samples, and two independent mouse models\",\n      \"pmids\": [\"32873636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Transcription factor Bach2 directly represses CD25 (IL-2Rα) expression in regulatory T cells; Bach2 deficiency in Tregs upregulates CD25 and IL-2R signaling, which partially compensates for poor resting Treg survival; Bach2 also suppresses CD25/IL-2R signaling in T follicular regulatory (Tfr) cells, and its deficiency prevents formation of highly differentiated Tfr cells and causes aberrant germinal center responses.\",\n      \"method\": \"Bach2 conditional knockout in Tregs, ChIP for Bach2 binding at CD25/Il2ra locus, flow cytometry for CD25 and IL-2R signaling markers, Tfr cell enumeration and GC analysis, in vitro IL-2 signaling assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct ChIP showing Bach2 binding at Il2ra locus combined with conditional KO and multiple functional readouts\",\n      \"pmids\": [\"33979619\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Tumor-specific CD8+ T cells (TSTs) co-express elevated CD25 and PD-1 and are more susceptible to stimulation by IL-2Rα-proficient agonists than by IL-2Rβγ-biased analogs; anti-PD-1 antitumor efficacy depends on activation of PD-1+CD25+ TSTs through autocrine IL-2–CD25 signaling; IL-2Rα-biased agonists (preserving CD25 activity) restore IL-2 signaling and synergize with anti-PD-1 to eradicate large established tumors in mouse models.\",\n      \"method\": \"Comparison of IL-2 variants (wild-type, IL-2Rα-biased, IL-2Rβγ-biased, non-α) in mouse tumor models; flow cytometry for CD25/PD-1 co-expression on TSTs; autocrine IL-2 signaling blockade experiments; anti-PD-1 combination experiments; human cancer patient IL-2 signature correlations\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple IL-2 variant comparisons in vivo with mechanistic dissection of CD25 role in autocrine signaling and anti-PD-1 response\",\n      \"pmids\": [\"37550516\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IL2RA (CD25) encodes the alpha chain of the high-affinity IL-2 receptor that, together with IL-2Rβ and the common γ-chain, forms a quaternary signaling complex (structurally defined at 2.3 Å) in which CD25 binding to IL-2 stabilizes a secondary surface for IL-2Rβ recruitment and γc docking, activating Jak1/Jak3 and downstream STAT5; CD25 undergoes clathrin-independent endocytic recycling (distinct from the β/γ chains which are ubiquitinated and degraded), is transcriptionally regulated by NF-κB/κB enhancers, TCR-Src kinase signals (early phase), and STAT5-bound superenhancers with chromatin looping (sustained phase), is repressed by SATB1-recruited HDAC and nucleosome-remodeling complexes and by Bach2, and is proteolytically shed as soluble CD25 by MMP-9; human IL2RA null mutation causes lymphoproliferation with hyperactivated CD8+ T cells and Treg dysfunction, and in AML cells IL2RA cell-autonomously promotes proliferation, blocks differentiation, and supports leukemic stem cell properties.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IL2RA (CD25) encodes the α-chain of the high-affinity interleukin-2 receptor and serves as a central regulator of T cell activation, differentiation, and immune homeostasis. Its transcription is governed by a κB/CArG enhancer in the promoter [PMID:2062658], a non-redundant STAT5-bound superenhancer with cooperative chromatin looping [PMID:29078395], positive regulation by FOXP3 downstream of CD28/PI3K-Akt signaling [PMID:18606654], and negative regulation by Bach2 [PMID:33979619]; TCR signal strength further tunes the duration of CD25 expression to bias CD4+ T cell fate between Th1 and Tfh [PMID:27936140]. CD25 localizes to lipid rafts to convert IL-2 receptor signaling from a Jak3-independent intermediate-affinity mode to a Jak3-dependent high-affinity proliferative mode [PMID:12121224], is proteolytically shed by MMP-9 [PMID:19878594], and undergoes clathrin-independent endocytosis with α-chain recycling while β/γ chains are ubiquitinated and degraded [PMID:15645712]. Functionally, CD25 is essential for regulatory T cell development and homeostasis via IL-2-dependent Foxp3 induction [PMID:17277105], drives immunopathology in hemophagocytic lymphohistiocytosis through IL-2 consumption by hyperactivated CD8+ T cells [PMID:30578871], promotes AML leukemogenesis and leukemic stem cell properties [PMID:32873636], and enables selective tumor rejection when engaged by CD25-biased IL-2 agonists that synergize with anti-PD-1 therapy [PMID:37550516].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Identifying the cis-regulatory elements controlling IL2RA transcription established that a κB enhancer and CArG box in the proximal promoter are required for activation-induced transcription, answering how T cell stimulation upregulates CD25.\",\n      \"evidence\": \"EMSA, nuclear run-on, and triplex-forming oligonucleotide inhibition in primary lymphocytes\",\n      \"pmids\": [\"2062658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signaling pathways converging on κB/CArG elements not defined\", \"Contribution of distal regulatory elements unknown at this stage\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Reconstitution of the IL-2R subunit–JAK signaling hierarchy showed that Jak3 unilaterally transphosphorylates Jak1 and that CD25 itself is not a JAK substrate, clarifying the kinase activation order downstream of the receptor complex.\",\n      \"evidence\": \"Baculovirus co-expression of recombinant IL-2R subunits with wild-type and kinase-dead JAK mutants; in vitro kinase assays\",\n      \"pmids\": [\"10037026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro reconstitution may not fully recapitulate membrane-proximal signaling dynamics\", \"Role of CD25 in positioning or stabilizing the signaling complex not addressed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrating that CD25 localizes to lipid rafts and switches IL-2R signaling from Jak3-independent anti-apoptotic to Jak3-dependent proliferative mode resolved how the α-chain qualitatively alters downstream signaling rather than merely increasing ligand affinity.\",\n      \"evidence\": \"Membrane fractionation and pharmacological inhibition in cells with and without CD25 expression\",\n      \"pmids\": [\"12121224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lipid raft localization mechanism (palmitoylation, protein interactions) not defined\", \"Findings from a single laboratory without independent replication\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showing that CD4+CD25+ Tregs suppress target T cells by downregulating CD25 on responder cells via CTLA-4 and membrane TGF-β1 established CD25 as both a marker and functional target of regulatory suppression.\",\n      \"evidence\": \"Blocking antibody experiments in thymocyte co-culture suppression assays with flow cytometry\",\n      \"pmids\": [\"12163566\", \"12893750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD25 downregulation is the primary or one of multiple parallel suppressive mechanisms unclear\", \"Molecular pathway from CTLA-4/TGF-β1 to CD25 transcriptional repression not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Characterizing CD25 endocytic trafficking revealed clathrin-independent internalization with α-chain recycling and ubiquitin-dependent degradation of β/γ chains, explaining how cells sustain CD25 surface expression while terminating signaling.\",\n      \"evidence\": \"Subcellular fractionation, receptor trafficking assays, and ubiquitination analysis\",\n      \"pmids\": [\"15645712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific E3 ubiquitin ligase(s) targeting β/γ chains not identified\", \"Quantitative recycling kinetics not established\", \"Review compilation of primarily single-lab data\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that IL-2 signaling through CD25 is required for TGF-β-mediated Foxp3 induction in naive T cells — and that other γc cytokines sustain but cannot initiate Foxp3 — established CD25/IL-2 as a non-redundant initiator of Treg commitment.\",\n      \"evidence\": \"IL-2-deficient mice, neutralizing antibodies, and cytokine substitution experiments\",\n      \"pmids\": [\"17277105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional mechanism linking IL-2R/STAT5 to Foxp3 locus opening not defined\", \"Whether CD25 expression itself feeds forward to stabilize Treg identity was not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"ChIP demonstration that FOXP3 is directly recruited to the CD25 promoter downstream of CD28/PI3K-Akt signaling defined a positive transcriptional feedback loop: FOXP3 → CD25 → IL-2 responsiveness → FOXP3 maintenance.\",\n      \"evidence\": \"Chromatin immunoprecipitation for FOXP3 at IL2RA promoter, PI3K and calcineurin inhibitors, CD28 costimulation in human CD4+ T cells\",\n      \"pmids\": [\"18606654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXP3 binding is sufficient or requires co-factors at the CD25 promoter not resolved\", \"Kinetics of the feedback loop in vivo not established\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identifying MMP-9 as the protease that sheds CD25 from the cell surface to generate soluble CD25 answered how sCD25 is produced and linked its generation to inflammatory stress.\",\n      \"evidence\": \"MMP-9 knockout mice, pharmacological inhibition, direct in vitro enzyme treatment of epithelial cells, immunobead assay for sCD25\",\n      \"pmids\": [\"19878594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP-9 is the sole sheddase on immune cells not tested\", \"Cleavage site on CD25 not mapped\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Linking IL2RA haplotypes to cell-type-specific differences in surface CD25 expression (confirmed at the RNA level by allele-specific expression) provided a mechanistic bridge between autoimmune disease-associated variants and altered IL-2 responsiveness.\",\n      \"evidence\": \"Polychromatic flow cytometry and allele-specific expression analysis in a large genotype-selectable human cohort\",\n      \"pmids\": [\"19701192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal variant(s) within haplotypes not pinpointed\", \"Regulatory element(s) affected by the variants not identified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that an MS-associated IL2RA polymorphism increases naive Th cell IL-2 responsiveness and GM-CSF-producing memory Th cell generation connected IL2RA genetic variation to a specific pathogenic effector mechanism in neuroinflammation.\",\n      \"evidence\": \"IL-2 responsiveness and GM-CSF production assays in genotyped primary human TH cells\",\n      \"pmids\": [\"25278028\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether GM-CSF skewing is directly causal for MS pathology not proven\", \"Single-lab finding without independent replication\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Showing that TCR signal strength controls the duration of CD25 expression, thereby biasing Th1 vs. Tfh fate, established CD25 as a signal-strength decoder that translates affinity into lineage commitment.\",\n      \"evidence\": \"Selective kinase inhibitors with time-resolved CD25 and pSTAT5 measurement in primary human CD4+ T cells\",\n      \"pmids\": [\"27936140\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo validation of the affinity–CD25 duration–fate relationship not performed\", \"Molecular mechanism linking sustained CD25 to Th1 gene program not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CRISPR deletion of individual STAT5-binding sites within the Il2ra superenhancer each reduced expression, demonstrating non-redundant cooperative function and chromatin looping as the mechanism for IL-2-driven Il2ra transcription.\",\n      \"evidence\": \"ChIA-PET chromatin interaction mapping, CRISPR-Cas9 mutagenesis of superenhancer elements in mice, ChIP-seq for STAT5\",\n      \"pmids\": [\"29078395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for cooperativity among superenhancer elements not resolved\", \"Whether human IL2RA superenhancer architecture mirrors mouse not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Genetic dissection in HLH models showed that CD25-dependent IL-2 consumption by hyperactivated CD8+ T cells drives immunological but not hematological disease features, separating CD25-mediated pathology from IFN-γ-dependent pathology.\",\n      \"evidence\": \"CD25 or IFN-γ genetic elimination in perforin-KO mice with LCMV infection; multiparameter disease scoring\",\n      \"pmids\": [\"30578871\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IL-2 consumption is cell-intrinsic to CD8+ T cells or also involves Tregs not fully delineated\", \"Therapeutic implications of targeting CD25 in HLH not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that IL2RA promotes AML proliferation, inhibits differentiation, and sustains leukemic stem cell properties established a cell-intrinsic oncogenic role for CD25 beyond its immune function.\",\n      \"evidence\": \"Genetic overexpression/knockdown, anti-IL2RA antibody, two mouse AML models, and primary patient samples\",\n      \"pmids\": [\"32873636\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway in AML cells (whether canonical IL-2/STAT5 or alternative) not fully defined\", \"Source of IL-2 ligand in the AML microenvironment not identified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identifying Bach2 as a direct transcriptional repressor of CD25 in Tregs revealed a brake on IL-2R signaling that tunes Treg homeostasis and Tfr control of germinal center responses.\",\n      \"evidence\": \"Bach2 conditional knockout in Tregs with ChIP/reporter assays, flow cytometry for CD25 and pSTAT5, Tfr and GC analysis\",\n      \"pmids\": [\"33979619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Bach2 and FOXP3 compete or cooperate at the CD25 locus not tested\", \"Mechanisms controlling Bach2 expression dynamics in Tregs not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showing that CD25-biased IL-2 agonists selectively expand tumor-infiltrating CD25+PD-1+ CD8+ T cells and synergize with anti-PD-1 therapy defined CD25 as a targetable node for cancer immunotherapy distinct from the β/γ-mediated pathway.\",\n      \"evidence\": \"IL-2 variant stimulation assays, multiple mouse tumor models, TIL phenotyping, anti-PD-1 combination studies, correlation with human patient data\",\n      \"pmids\": [\"37550516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether long-term memory is generated by CD25-biased stimulation not assessed\", \"Potential for Treg co-expansion in patients not fully addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for how CD25 lipid raft localization switches JAK signaling mode; the identity of specific E3 ligases targeting IL-2Rβ/γ for degradation; whether the human IL2RA superenhancer is architecturally and functionally equivalent to the mouse locus; and the source and role of autocrine/paracrine IL-2 in the AML niche.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Structural model of CD25 in lipid raft context absent\", \"E3 ligase(s) for IL-2Rβ/γ ubiquitination unidentified\", \"Human superenhancer architecture at IL2RA not mapped at element-level resolution\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [1, 2, 13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 4, 6]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 5, 8, 11, 13]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 9, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 9, 12, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 10, 14]}\n    ],\n    \"complexes\": [\n      \"IL-2 receptor complex (IL-2Rα/β/γc)\"\n    ],\n    \"partners\": [\n      \"IL2RB\",\n      \"IL2RG\",\n      \"JAK3\",\n      \"JAK1\",\n      \"STAT5\",\n      \"FOXP3\",\n      \"BACH2\",\n      \"MMP9\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"IL2RA (CD25) encodes the alpha chain of the interleukin-2 receptor, which assembles with IL-2Rβ and the common γ-chain to form the high-affinity IL-2 receptor quaternary complex; the 2.3 Å crystal structure shows that CD25 binding to IL-2 stabilizes a secondary surface for IL-2Rβ recruitment and subsequent γc docking, enabling Jak1/Jak3–STAT5 signaling [PMID:16293754, PMID:7973659]. Transcription of IL2RA is activated in two phases—an early TCR/Src-kinase-dependent phase and a sustained JAK3/STAT5-dependent phase operating through non-redundant STAT5-bound superenhancer elements with chromatin looping—and is repressed by SATB1-recruited HDAC/nucleosome-remodeling complexes and by Bach2 [PMID:29078395, PMID:12374985, PMID:33979619, PMID:27936140]. After internalization via a clathrin-independent pathway, CD25 recycles to the plasma membrane while the β and γ chains are ubiquitinated and degraded, and membrane CD25 can be proteolytically shed as soluble CD25 by MMP-9 [PMID:15645712, PMID:19878594]. Homozygous loss-of-function IL2RA mutations in humans cause immune dysregulation with CD8+ T-cell lymphoproliferation and Treg dysfunction, and in AML, IL2RA cell-autonomously promotes proliferation, blocks differentiation, and sustains leukemic stem cell properties [PMID:23416241, PMID:32873636].\",\n  \"teleology\": [\n    {\n      \"year\": 1984,\n      \"claim\": \"Molecular cloning of the IL2RA cDNA established that a single gene encodes the IL-2-binding α chain, resolving the molecular identity of the receptor subunit and revealing alternative splicing that abolishes ligand binding.\",\n      \"evidence\": \"cDNA cloning with expression in COS cells and IL-2 binding assay\",\n      \"pmids\": [\"6090948\", \"6090949\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No knowledge of additional receptor subunits required for high-affinity binding\", \"Signaling mechanism unknown\", \"No structural information\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Co-expression of IL-2Rα with the newly cloned IL-2Rβ reconstituted high-affinity IL-2 binding, establishing that the high-affinity receptor is a multi-subunit complex and that CD25 alone forms only the low/intermediate-affinity state.\",\n      \"evidence\": \"Co-expression of IL-2Rα and IL-2Rβ cDNAs in T lymphoid cells with IL-2 binding assays\",\n      \"pmids\": [\"2785715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"γc subunit not yet identified\", \"No structural basis for cooperativity\", \"Downstream signaling effectors unknown\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Identification of κB enhancer and CArG box elements in the IL2RA promoter as essential cis-regulatory regions established the first transcriptional control mechanism, later extended by the finding that HTLV-I tat-I transactivates through the same region.\",\n      \"evidence\": \"Triplex oligonucleotide targeting of promoter combined with EMSA, nuclear run-on assays in lymphocytes, and promoter-CAT reporter deletion mapping\",\n      \"pmids\": [\"2062658\", \"3030566\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors beyond NF-κB not identified\", \"Chromatin-level regulation unknown\", \"No in vivo validation of promoter elements\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstration that Jak1 associates with IL-2Rβ and Jak3 with γc, with both required for IL-2 signaling, defined the proximal kinase cascade downstream of the receptor complex that CD25 assembly enables.\",\n      \"evidence\": \"Co-immunoprecipitation and reconstitution in Jak3-negative fibroblasts bearing IL-2R subunits\",\n      \"pmids\": [\"7973659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Order of Jak activation unclear\", \"STAT substrate specificity not fully delineated\", \"How CD25 presence vs absence alters Jak activation not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that SATB1 recruits NURD HDAC and ACF1/ISWI nucleosome-remodeling complexes to the IL2RA locus, with ectopic IL2RA expression in SATB1-null thymocytes, revealed that chromatin architecture actively represses IL2RA transcription in non-activated cells.\",\n      \"evidence\": \"ChIP for histone acetylation, nucleosome positioning assays, SATB1 knockout mice\",\n      \"pmids\": [\"12374985\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay between SATB1 repression and NF-κB activation not defined\", \"Enhancer architecture not mapped\", \"Whether other locus-specific repressors exist was unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Trafficking studies resolved that CD25 follows a clathrin-independent endocytic pathway and recycles to the surface, while IL-2Rβ/γc are ubiquitinated and degraded, explaining how CD25 is maintained for sustained IL-2 sensing even as signaling chains are turned over.\",\n      \"evidence\": \"Endocytosis assays, subcellular fractionation, ubiquitination analysis\",\n      \"pmids\": [\"15645712\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular sorting signals on CD25 that direct recycling not identified\", \"Recycling kinetics not quantified in vivo\", \"Relationship to lipid raft localization not established\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"The 2.3 Å crystal structure of the quaternary IL-2/IL-2Rα/IL-2Rβ/γc complex revealed that CD25 binding to IL-2 allosterically stabilizes the IL-2Rβ-binding surface and that γc docking uses degenerate contacts, providing the structural basis for high-affinity receptor assembly and explaining X-SCID mutations.\",\n      \"evidence\": \"X-ray crystallography of the full ectodomain quaternary complex\",\n      \"pmids\": [\"16293754\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transmembrane and intracellular domain organization unknown\", \"How structural changes propagate to Jak activation not resolved\", \"No dynamics information from static crystal\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"MMP-9 was identified as the protease responsible for shedding membrane CD25 as soluble CD25, validated by MMP-9 knockout, pharmacologic inhibition, and direct enzyme treatment, establishing a mechanism for the well-known soluble IL-2Rα found in serum.\",\n      \"evidence\": \"MMP-9 knockout mice, doxycycline inhibition, in situ zymography, Western blot of CD25 in corneal epithelial cells\",\n      \"pmids\": [\"19878594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP-9 is the sole sheddase on immune cells not confirmed\", \"Cleavage site on CD25 not mapped\", \"Functional consequence of sCD25 on IL-2 signaling not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Disease-associated IL2RA polymorphisms were shown to regulate CD25 surface protein levels in a cell-type-specific manner (confirmed by allele-specific expression), mechanistically linking autoimmune risk variants to quantitative differences in IL-2 receptor expression rather than coding changes.\",\n      \"evidence\": \"Polychromatic flow cytometry for CD25 across immune subsets, genotype-stratified analysis, allele-specific expression\",\n      \"pmids\": [\"19701192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal regulatory variant not pinpointed\", \"Epigenomic mechanism of cell-type specificity unknown\", \"Whether variants alter enhancer–promoter contacts not tested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A homozygous IL2RA null patient demonstrated that CD25 is essential for immune homeostasis: its loss causes pronounced CD8+ T-cell lymphoproliferation with STAT5-activated tissue-infiltrating CD8+ cells and impaired antigen-specific responses, while Tregs retain residual IL-2 responsiveness.\",\n      \"evidence\": \"Immunological phenotyping of IL2RA-null patient with flow cytometry, STAT5 phosphorylation, antigen-specific assays, and tissue biopsy\",\n      \"pmids\": [\"23416241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether residual Treg function is mediated by intermediate-affinity IL-2R or alternative cytokines unclear\", \"Only one patient studied at molecular depth\", \"Mechanism of preferential CD8 hyperactivation not explained\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"CRISPR-Cas9 deletion of individual STAT5 binding sites within the Il2ra superenhancer each independently reduced IL-2-induced Il2ra expression, establishing that superenhancer elements are non-redundant and that STAT5-mediated chromatin looping is the sustained-phase transcriptional mechanism for IL2RA.\",\n      \"evidence\": \"ChIA-PET chromatin interaction mapping, CRISPR-Cas9 deletion of superenhancer elements in mice, ChIP-seq for STAT5\",\n      \"pmids\": [\"29078395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How superenhancer integrates with the early TCR/Src-dependent phase not resolved\", \"Whether human IL2RA superenhancer has identical architecture not tested\", \"Contribution of individual STAT5 sites to Treg vs effector T cell expression not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"IL2RA was shown to cell-autonomously promote AML cell proliferation, block differentiation, and maintain leukemic stem cell properties—a non-immune function validated by genetic knockdown and antibody inhibition in two mouse AML models—expanding CD25's role beyond immune regulation.\",\n      \"evidence\": \"shRNA knockdown, overexpression, and anti-CD25 antibody in human AML cells, primary patient samples, and two mouse AML models\",\n      \"pmids\": [\"32873636\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling pathway in AML cells not fully characterized\", \"Whether AML CD25 signals through canonical Jak/STAT5 or alternative pathways unknown\", \"Whether sCD25 shedding contributes to AML phenotype not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Bach2 was identified as a direct transcriptional repressor of CD25 in Tregs, with Bach2 deficiency upregulating CD25 and IL-2R signaling to partially compensate for poor Treg survival; this established a second chromatin-level repressive mechanism complementary to SATB1.\",\n      \"evidence\": \"Bach2 conditional knockout in Tregs, ChIP for Bach2 at Il2ra locus, flow cytometry, Tfr and GC analysis\",\n      \"pmids\": [\"33979619\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Bach2 and SATB1 operate on the same or distinct regulatory elements not determined\", \"Molecular interplay between Bach2 repression and STAT5 superenhancer activation not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Tumor-specific CD8+ T cells co-expressing CD25 and PD-1 depend on autocrine IL-2–CD25 signaling for anti-PD-1 responsiveness, and IL-2Rα-biased agonists synergize with checkpoint blockade, establishing CD25 as a critical node in antitumor immunity.\",\n      \"evidence\": \"Comparison of IL-2 variants (IL-2Rα-biased vs IL-2Rβγ-biased) in mouse tumor models, autocrine IL-2 blockade, anti-PD-1 combination, human patient correlation\",\n      \"pmids\": [\"37550516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which autocrine IL-2 is produced by TSTs not defined\", \"Whether CD25-high TSTs represent a distinct differentiation state or activation state not resolved\", \"Translation to human clinical anti-PD-1 settings not validated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for full-length receptor transmembrane signaling, the identity of sorting signals directing CD25 recycling, how disease-associated non-coding variants alter superenhancer architecture cell-type-specifically, and the signaling pathway through which CD25 drives AML stem cell properties.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length IL-2R structural model including transmembrane/intracellular domains\", \"CD25 recycling sorting signal not mapped\", \"Causal autoimmune-risk variant–enhancer interactions not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 3, 14, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 4, 13, 15]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 8, 9, 12, 18, 22, 25, 26]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 8, 14, 17, 20, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [16, 18, 19, 24]}\n    ],\n    \"complexes\": [\n      \"IL-2 receptor (IL-2Rα/IL-2Rβ/γc)\"\n    ],\n    \"partners\": [\n      \"IL2RB\",\n      \"IL2RG\",\n      \"IL2\",\n      \"JAK1\",\n      \"JAK3\",\n      \"STAT5A\",\n      \"SATB1\",\n      \"BACH2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}